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Ankylosing spondylitis (AS) is a chronic inflammatory joint disease
that affects the axial skeleton and is characterised by sacroiliitis and
spondylitis. The disease onset typically occurs during the adolescence
and early adulthood. AS typically presents with low back pain and
stiffness which may be mistaken by these young people as
musculoskeletal strains and sprains from sports or work activities.
Not many are aware of possible underlying rheumatic diseases and
present themselves for medical attention. With time, the ascending
spondylitis results in significant stiffness of the lumbar, thoracic and
cervical spine. A patient with advanced disease often adopts a
stooped posture with limitation in chest expansion and restriction in
movement of the neck. This often results in significant compromise in
the activities of daily living. Some patients may also have peripheral
arthritis, of which the hip joints are commonly involved and often
indicates poor prognosis.
There have been struggles in the management of these patients in
terms of pharmacological therapy. In contrast to rheumatoid arthritis,
disease modifying anti-rheumatic agents in AS have not been shown
to be efficacious in clinical studies. Patients have been left with no
choice but regular non-steroidal anti-inflammatory drugs for
symptomatic relief and non-pharmacological therapy to maintain the
mobility of the spine.
The emergence of biologic agents has revolutionised the management
of these patients. Tumour necrosis factor-alpha (TNF ), a pro-
inflammatory cytokine has been found in sacroiliac joint aspirate from
patients with AS. Various anti-TNF biological agents have been
shown to be efficacious in symptom control and radiological
improvement. Early recognition of the disease and selection of
patients based on the clinical profile and immunogenetics can
hopefully help us to identify high risk patients for cost-effective
treatment and to provide us with more information on predicting
prognosis and clinical response to biologic treatment.
Novel surgical treatment has also shown early promising results in
terms of correction of body posture and improvement in quality of life
for these patients.
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Introduction
Spondyloarthropathies are chronic inflammatory
rheumatic disorders that are characterised by sacroiliitis,
ascending spondylitis, enthesitis, extra-articular
manifestation and genetic factor predisposition (HLA
B27). They include ankylosing spondylitis (AS), psoriatic
arthritis, reactive arthritis, and arthritis associated with
inflammatory bowel disease.
Patients suffering from early spondyloarthropathies may
not seek medical attention because of lack of awareness
of their underlying conditions. Patients with advanced
disease have significant restriction of movement of the
trunk and neck leading to impairment in their activities
of daily living. Early diagnosis can help counsel these
patients and maintain spinal mobility by physiotherapy
and achieve symptomatic control by the use of non-
steroidal anti-inflammatory drugs. Recent advances in
medical treatment using anti-tumour necrosis factor-
(anti-TNF- ) have shown significant symptomatic and
radiological improvement1. Early diagnosis of
spondyloarthropathies and referral to specialists is
important in the management of these patients. Early
diagnosis remains the current challenge in the context of
different sets of diagnostic criteria which currently exist.
It is important that the diagnostic criteria are useful to
differentiate patients from the background population.
Table 1 shows an example of such diagnostic criteria for
which AS is commonly used. In this article clinical features
that can help in early diagnosis of spondyloarthropathies
at the level of the primary health care physicians are discussed.
Seronegative Spondyloarthropathies
Ankylosing spondylitis
This is a prototypic inflammatory arthropathy affecting
joints of the axial skeleton. The male to female ratio is 3:1.
The age at disease onset is around 20 years. The disease
is extremely strongly associated with HLA B27. About
20% of these patients also have peripheral arthritis that
involves particularly the hips, shoulders and knees.
Enthesitis, inflammation affecting sites of insertion of
ligaments, tendons and joint capsule into bone, is
common. Fibrocartilage, such as sacroiliac (SI) joints and
rib cartilages, is involved. Some patients may also suffer
from extra-articular manifestations including iritis,
aortitis and apical lung fibrosis.
Psoriatic arthropathies
Psoriasis affects 1-2% of the general population and
around 10% of patients with skin psoriasis develop
arthritis. The disease may start at any age. Joint
involvement occasionally occurs prior to the
development of psoriatic skin disease. About 70% of
patients with psoriatic arthritis show evidence of nail
dystrophy including pitting, ridging and onycholysis
compared with only 20% of patients without arthritis.
Psoriatic arthropathies may take one of the five patterns
of joint involvement: distal interphalangeal joints,
o l igoart icular , rheumatoid arthr i t i s l ike ,
spondyloarthropathy and arthritis mutilans.
Reactive arthritis
This inflammatory joint disease typically follows a
genitourinary or gastrointestinal infection. Gram
negative bacteria including Chlamydia trachomatis,
Shigella, Salmonella, Yersinia and Campylobacter have
been implicated in the underlying pathogenesis. There is
typically arthritis involving lower limb joints that
resolves within 3-6 months. Around 40% of patients
develop persistent erosive arthritis.
Enteropathic arthropathies
Approximately 10% of patients with inflammatory bowel
disease develop peripheral arthritis. Arthropathies are
more commonly seen in patients with Crohn's disease
than in ulcerative colitis. Oligoarticular involvement of
lower limb joints may develop in some patients. AS
occurs in around 5-10% of patients with Crohn's disease.
Early Diagnostic Features Of
Spondyloarthropathies
Back pain
Limited spinal mobility is a cardinal feature of
seronegative spondyloarthropathies. Low back pain is
one the earliest symptoms of lumbar spondylitis. A
distinction should be made in regard to the nature of
pain being inflammatory or mechanical. Mechanical
back pain is brought on by exercise. Inflammatory back
pain should be alerted if it is of insidious onset in a
patient younger than 40 years that persists for more
than 3 months and is associated with morning stiffness
that improves with exercise. Clinical history has been
found to be useful as a screening tool for detection of
patients with AS in the out-patient setting2.
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Inflammatory back pain gives satisfactory sensitivity
(71.4%) and specificity (77.3%) in the diagnosis of early
spondyloarthropathies 3.
The early plain radiographic abnormalities of spondylitis
may appear as marginal sclerosis with shiny corners at
the margin of the intervertebral disc which may best be
seen in MRI. New bone along the anterior vertebral
margin results in squared appearance of lumbar
vertebrae. With time, the spinal ligaments ossify forming
vertically oriented bony bridges between the vertebral
bodies called syndesmophyte. The posterior apophyseal
and costotransverse joints become fused. In advanced
disease the whole spine is rigidly fused and becomes a
solid block of bone and is known as 'bamboo' spine.
Chest wall pain and limited chest expansion
Anterior chest pain may occur as a result of arthritis of
the manubriosternal, sternoclavicular and costosternal
joints. Together with limited chest expansion, chest wall
pain is commonly seen in thoracic spinal involvement.
Reduced chest expansion, especially of less than 5 cm,
represents advanced forms of spondylitis and is of
limited value in differentiating normal from early cases
of spondylitis.
Restricted spinal movement
The clinical course of spondyloarthropathies is
characterised by ascending spondylitis with gradual
sequential involvement of the lumbar, thoracic and cervical
spine. Limited spinal mobility is one of diagnostic criteria
for spondyloarthropathies. Ankylosis is a late feature and is
a result of ossification of ligaments, vertebrocostal and
sternocostal joints. This eventually forms the classical
"bamboo spine". Limitation in flexion and extension,
rotation and lateral flexion of the lumbar spine may be
detected in patients with early disease. However, the
measurement is poorly standardised in clinical practice.
Limited spinal motion appears to reflect the disease
duration rather than a diagnosis of early disease.
Sacroiliitis
Unilateral or bilateral buttock pain is one of the earliest
symptoms of sacroiliitis. The pattern of involvement of
the SI joints being unilateral or bilateral may also give a
clue to the underlying diagnosis. AS typically involves
both SI joints whereas unilateral sacroiliitis is more
usually found in psoriatic spondyloarthropathy, Reiter's
disease and enteropathic spondyloarthropathies. There
may be tenderness over one or both SI joints on palpation
but radiological imaging offers higher sensitivity for
detection. Plain X-ray of the SI joints is simple to
perform. Despite the high specificity, it showed a poor
sensitivity in diagnosing spondyloarthritis3. Radiological
changes usually take three to seven years to develop and
are the characteristics of advanced disease. A grading
system has been devised depending on the chronic
radiographic changes (Table 1). The earliest radiological
change (Grade I) involve irregular fuzzy outlines of the
joint margins that can be non-specific and may be
difficult to differentiate from degenerative and infective
changes of the SI joints. Grade 2 lesions show up as early
erosion with sclerosis of the joint but may take years to
develop. Eventually the process leads to obliteration of
the joint space (Grade 4).
Computerized Tomography (CT) of the SI joints may
allow detection of structural changes and is superior to
conventional radiography for detecting bony changes
related to sacroiliitis. Magnetic resonance imaging (MRI)
can detect bone oedema and fatty conversion in the
subchondral marrow, features of early sacroiliitis. It can
also demonstrate joint inflammation in the synovial
joint4. However, the MRI grading has not been
standardised and their role in diagnosis is still under
investigation. There is no firm consensus on the relative
merits of CT versus MRI in the diagnosis of sacroiliitis.
MRI is superior in the detection of both cartilage
abnormalities and erosions whereas CT is superior to
MRI in the detection of new bone formation and
ankylosis. Scintigraphy is an alternative method to detect
sacroiliitis but the sensitivity and specificity is lower than
with other imaging techniques5. Areas of increased
uptake of radioisotope may suggest pseudoarthrosis or
fractures that may complicate the clinical course in
patients with advanced disease.
Family history
The development of spondyloarthropathies is strongly
linked to HLA B27 haplotype. The haplotype is prevalent
in all forms of spondyloarthropathies especially AS and
is inherited in an autosomal co-dominant fashion. The
risk of developing AS in a person with positive family
history is 20 to 40 times higher than the general
population. Fifty percent of first degree relatives of the
HLA-B27 positive individuals possess the antigen. The
prevalence of HLA B27 among spondyloarthropathies
and general population is shown in Table 2. HLA B27 is
present in around 10% of normal population but in 90%
of patients with AS. It has a high negative predictive
value and is useful in early screening of the disease. The
presence of HLA B27 and/or family history of
spondyloarthropathies show high specificity in diagnosis
when associated with inflammatory back pain3.
Enthesitis
Inflammation of the entheses, the sites of ligamentous
attachment to bones, is one of the prominent features of
spondyloarthropathies. Patients commonly complain of
pain over the heel or the sole of the foot on walking.
Tenderness can be elicited on the Achilles tendon and
plantar fascia for detection of enthesitis at these sites.
Clinical examination has only low sensitivity in detecting
enthesitis. The role of MRI and ultrasonography as a
more accurate tool in detecting enthesitis is currently
under evaluation.
Peripheral arthritis
Some patients with spondyloarthropathies also have
peripheral arthritis and may present with dactylitis,
asymmetrical monoarthritis, oligoarthritis or a pattern
simulating rheumatoid arthritis. There is usually a
predominant involvement of joints of the lower limbs. In
Reiter's disease, few joints are involved and there may be
calcaneal erosions with spur formation that can be
detected on Xray.
Extra-articular features
Extra-articular manifestations of spondyloarthropathies
include inflammatory bowel disease, psoriasis,
urethritis and anterior uveitis. These specific features
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help to differentiate the particular sub-types of
spondyloarthropathies. For example, anterior uveitis is
more common in patients with AS (a prevalence of 40%)
and skin psoriasis and nail dystrophy suggest psoriatic
arthropathy. Other features such as fibrosing alveolitis,
aortic incompetence, amyloidosis, balanitis and iritis
may aid in diagnosis of spondyloarthropathies.
Conclusion
With the development of new therapies, there is a need
to recognise patients with early disease who have worse
prognosis. The inflammatory nature of back pain
obtained from clinical history is helpful in the early
diagnosis of spondyloarthropathies. Clinical sacroiliitis
lacks the specificity and radiological sacroiliitis is too
insensitive to be useful in early diagnosis. The emerging
technique of ultrasound and MRI are future tools in
assisting early diagnosis. Other useful information
includes tissue-typing and family history. Particular
extra-articular features help to differentiate the sub-
types of spondyloarthropathies.
With the development of new biologic therapies, early
recognition of patients with early stage of disease, together
with information from future researches on identifying
patients with worse prognosis and better response to
treatment for earlier therapy will be of great benefit.
Clinical criteria
Low back pain and stiffness for >6 months that improves with exercise
but is not relieved by rest
Limitation of motion of the lumbar spine in both sagittal and frontal
planes
Limitation of chest expansion relative to normal values for age and sex
Radiological criteria
> grade II bilateral sacroiliitis
Grade III or IV sacroiliitis unilaterally
Table 1. Modified New York criteria for ankylosing
spondyilitis.
Grade X-ray findings
0 Normal
1 Suspicious
2 Sclerosis, some erosion
3 Severe erosion, widening of joint space, minor ankylosis
4 Complete ankylosis
Table 2. Grading of chronic radiographic changes of the
sacroiliac joint in ankylosing spondylitis.
Spondyloarthropathies Percentage (%)
Ankylosing spondylitis 90
Reactive arthritis 75
Psoriatic arthropathy 50
Enteropathic arthropathy 50
General population 10
Table 3. Prevalence of HLA B27 haplotypes in various
spondyloarthropathies
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MCHK CME Programme Self-assessment Questions
Please read the article entitled "Early diagnosis of spondyloarthropathies" by Dr Ho-yin Chung, Dr. Mo-yin Mok and
complete the following self-assessment questions. Participants in the MCHK CME Programme will be awarded 1 CME
credit under the Programme for returning completed answer sheet via fax (2865 0345) or by mail to the Federation
Secretariat on or before 30 November 2006. Answers to questions will be provided in the next issue of The Hong Kong
Medical Diary.
Questions 1-10: Please choose the best answer.
1. Which of the following diseases do not belong to spondyloarthropathies?
a. Ankylosing spondylitis
b. Rheumatoid arthritis
c. Psoriatic arthropathy
d. Inflammatory bowel disease related arthritis
2. What of the following is not a pathological characteristic of spondyloarthropathies?
a. Sacroiliitis
b. Enthesitis
c. Osteoarthritis
d. Spondylitis
3. Which of the following is not an early symptom of presentation of spondyloarthropathy?
a. Neck pain
b. Back pain
c. Buttock pain
d. Back stiffness
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4. Which of the following is most sensitive in the detection of early sacroiliitis?
a. Plain X ray
b. Magnetic Resonance Imaging
c. Scintigraphy
d. Tenderness on sacroiliac joint
5. Which of the following pattern of peripheral arthritis is seen in spondyloarthropathies?
a. Oligoarticular
b. Rheumatoid arthritis-like
c. Monoarticular
d. All of the above
6. Which of the following are predictive of psoriatic arthritis in a patient with skin psoriasis?
a. Nail dystrophy
b. Extensive psoriatic skin plaques
c. Erythroderma type of skin psoriasis
d. Family history of skin psoriasis
7. Which of the following is not an extra-articular manifestation of spondyloarthropathies?
a. Cardiac valvular defect of aortic regurgitation
b. Uveitis
c. Generalised lymphadenopathies
d. Apical lung fibrosis
8. Which of the following is poor prognostic factor in spondyloarthropathies?
a. Male
b. Female
c. Hip involvement
d. Family history
9. Which of the following is compatible with advanced spondyloarthropathies?
a. Restricted movement of the neck
b. Limited chest expansion
c. Bamboo spine on Xray of the lumbosacral spine
d. All of the above
10. What is the biologic treatment that has currently been shown to be efficacious in the treatment of ankylosing spondylitis?
a. Anti-CD20 antibody
b. Anti-tumour necrosis factor-alpha therapy
c. Methotrexate
d. Mycophenolate mofetil
Please return the completed answer sheet to the Federation Secretariat on or before 30 November 2006 for
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists)
self-assessment questions.
1 2 3 4 5
Name (block letters):____________________________________ HKMA No.:
___ ___ - ___ ___ ___ ___ X X (x)HKID No.:
____________ ______________________
____________ ______________________
Others Membership No.
ContactTelNo.:_________________________________________________
6 7 8 9 10
ANSWER SHEET FOR NOVEMBER 2006
Answers to October 2006 issue
Endocrine Hypertension-Strategy for Screening and Workup
1 . C 2 . C 3 . B 4 . A 5 . D 6 . C 7 . C 8 . A 9 . D 10 . A
Early diagnosis of spondyloarthropathies
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Ankylosing spondylitis (AS) is a multifactorial chronic
rheumatic disease. The precise aetiology remains
unclear. It is likely to involve interactions between
genetic and environmental factors as evidenced by the
variable clinical morbidity in different racial groups,
familial congregation and the strong association with
HLA-B27 in the major histocompatibility complex
(MHC) region. There are more evidences from
aggregation studies suggesting that more than one gene
are involved in AS, including genes in both MHC and
non-MHC regions. Genome-wide linkage analysis and
disease-association studies are the main approaches to
identify susceptible genes.
Major histocompatibility complex (MHC), located on
chromosome 6p, is a multigene family comprises of
genes in close linkage disequilibrium. It is closely
related to function of the immune system and the
product of this gene is a highly complex extracellular
transmembrane protein called MHC antigen. Genetic
epidemiology study showed that 40%-50% of the
genetic component may be contributed by genes in the
MHC region. Rubin et al first demonstrated this strong
linkage between MHC region and AS in 15 multiplex
AS families. When the population association of HLA-
B27 with AS was taken into account, the maximum lod
score was 7.5 at £c = 0.05. In accordance with Rubin's
finding, all subsequent whole genome linkage
investigations demonstrated strongest linkage between
MHC region and AS suggesting the major role on
genetic influence of the MHC region on the
development of AS.
The genetic marker, HLA-B27, is present in 80 to 98
percent of AS patients. HLA-B27 accounts for only 16
percent of the total genetic risk for the disease, whereas
the MHC on its own accounts for about half of the
genetic variability for AS. The precise role of HLA-B27
in the pathogenesis of AS remains unclear and is likely
to be heterogeneous and involves more than one
mechanism. HLA-B27 is a family of 31 different alleles.
Studies indicate that the relatively common alleles
(subtypes), HLA-B*2705, B*2704, and B*2702, are
strongly associated with AS. HLA-B*2706 is prevalent
in Southeast Asia. The strong association with most
subtypes of HLA-B27 supports the view that the disease
is due to a genetically determined immune response to
environmental factors in susceptible individuals.
Arthritogenic peptide and molecular mimicry are
hypotheses on the antigen presenting function of HLA-
B27 postulated to relate to disease development.
Different subtypes of HLA-B27 may differ in their
ability to present peptides to autoreactive cytotoxic T
cells. However, certain aberrant immunobiological
features of HLA-B27, such as misfolding and heavy
chain dimerisation suggest that the underlying
pathogenic mechanisms may be unrelated to its
physiological function. We hope that more data from X-
ray diffraction studies on individual peptides in the
different HLA-B27 alleles can explain the role of B27
molecule in the pathogenesis of AS. Other HLA
subtypes may also contribute to the genetic
susceptibility to AS. HLA-B60 has been demonstrated to
be associated with susceptibility to AS in some studies,
whereas other studies support a role for HLA-
DRB1*0101 and 1501 and other HLA factors (B7-Creg,
B38, B39, DR1, DR8).
Tumour necrosis factor- (TNF- ) promoter allele
polymorphism has been postulated to be involved in
the predisposition to AS. TNF has been shown to be
involved in the pathogenesis of a number of
autoimmune diseases. Genome scans revealed the
location of TNF gene in the susceptibility region of
MHC segment in AS. Anti-tumour necrosis factor (TNF)-
　therapies, infliximab and etanercept, have been
shown in clinical trials to be efficacious in the treatment
of AS. However, there are controversial findings on the
association of TNF and AS from different association
analysis studies world-wide. We performed a meta-
analysis on this subject and found no significant
association of AS with TNF promoter 308G/A and
238G/A polymorphism by stochastic effect model. As
national publications in China on this subject are few
and that TNF and B27 linkage disequilibrium were
not analysed together, we suggest further research on
linkage disequilibrium in different races by strict match
control.
Family studies strongly suggest additional genetic
factors (including non-HLA genes) other than HLA-B27
or its subtypes, in predisposition to AS. Around 69
percent of the genetic effect may be contributed from
outside the HLA region. Genome-wide scans from
Oxford and the North American Spondylitis
Consortium (NASC) and other studies have identified
strongly implicated genes in other regions on
chromosomes 1q, 2q, 3q, 5q, 6p, 11q, 16q. 10q, 16q, 17p,
19q and so on. However there has not been significant
agreement in conclusions from the candidate gene
analyses completed by NASC and other studies.
Controversial results were found in regard to the
relation between IL-1 and AS. Recently, Maksymowych
et al genotyped AS samples in three Canadian
populations using a panel including 38 SNPs across the
IL-1 gene cluster, and found significant associationwith
Present Status on the Genetics of
Ankylosing Spondylitis
Prof. Jieruo Gu MD
Professor of Medicine, Department of Rheumatology
The 3th Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
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AS in 18 SNPs, among which rs3783526 (IL1A) and
rs1143627 (IL1B) are the most significantly linked. On
the contrary, Kim et al found no difference of IL-1 gene
cluster polymorphism between 205 AS patients and 200
controls. Djouadi et al also reported a negative finding.
A weak association of AS with a variable number of
tandem repeats (VNTR) in intron 2 of interleukin 1
receptor antagonist (IL1RN) and an association of 2
synonymous single nucleotide polymorphisms (SNP) in
exon 6 of IL1RN and their haplotypes in a large
Canadian cohort of AS patients has recently been
described. However, the NASC study examining the
same SNP, revealed no evidence for linkage of AS to
IL1RN. Although the level of Matrixmetalloproteinase
III (MMP3) is found to be elevated in synovial biopsies
in AS patients with active disease, no association or
linkage of MMP3 SNP could be demonstrated in the
NASC families. Likewise, the gene of TGF-beta 1, a
cytokine found elevated in serum of AS patients have
been studied. These studies did not show significant
association with genes that lie in chromosome 19 where
the TGF-beta 1 gene is located. CYP2D6, a gene found
on chromosome 22q, is found weakly associated with
AS in German and British patients. No correlation
between the sex biases of AS susceptibility and X-
chromosome has been found.
Current genetic research of genome-wide scans using
microsatellite markers for AS have largely been
disappointing. The MHC is likely the major contributor
in susceptibility to AS. The biggest challenge ahead lies
in identifying the non-MHC contribution to the
pathogenesis of AS. Success in this area in future should
focus on using dense SNP screening of the genome
which can help identify individuals with poor prognostic
factors and their response to novel treatments.
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Introduction
Ankylosing spondylitis is an inflammatory condition of
the spine usually starting in young adulthood. The
predominant symptom is pain, later followed by
stiffness. The sacro-iliac joints and the spine are most
commonly affected but the peripheral joints may also be
involved. In the study of 100 patients, Ho el al found
peripheral joint involvement in 58 patients, the most
common being the hips and knees. 1
As the spine is concerned, there are three aspects in
ankylosing spondylitis that are of particular surgical
interest. They are severe kyphosis deformity,
pseudarthrosis and spinal fractures. For the peripheral
joints, total hip arthroplasty has become a well
established treatment for patients with significant hip
involvements.
Kyphosis in Ankylosing Spondylitis
Kyphosis may affect the cervical and thoracic spine. The
kyphotic posture put the spine in mechanical
disadvantage. Owing to the increased level arm, more
force is required to maintain the up-right posture which
makes patients tiring in walking and standing (Fig 1).
Sagittal mal-alignment together with the stiff spine also
impairs the visual angles of the patients; making them
difficult to look forward on standing and walking. In
order to maintain a good forward visual arc, patients
need to flex their knees, thus resulting in a very tiring
posture (Fig 2) the severe kyphosis may also cause
difficulty in sitting, feeding, sleeping, impair
diaphragmatic breathing, and psycho-social function.
Surgical interventions should be considered in patients
with severe fixed kyphosis that causes significant
symptoms or disabilities.
Three types of extension osteotomies have been
described to correct kyphosis in ankylosing spondylitis,
namely Smith Peterson opening wedge osteotomy (Fig
3), Thomason closing wedge osteotomy (Fig 4) and poly-
segmental dorsal wedge osteotomy (Fig 5). For thoraco-
lumbar kyphosis, the osteotomy is usually at the lumbar
spine for lesser chance of neurological complications and
more effective in correcting the sagittal mal-alignment
compared with osteotomy at thoracic levels2 (Fig 6). For
cervical or cervico-thoracic kyphosis, the osteotomy is
usually at cervico-thoracic junction to correct the gaze
angle and maintain the sagittal alignment of the spine 3
(Fig 7) Kim et al prospectively studied 45 patients having
received extension osteotomies for kyphosis in
ankylosing spondylitis, there were significant
improvements in sagittal balance of the spine, gaze
angle, overall function, indoor activities levels, outdoor
activities levels and back pain after the operation.4 Van
Royen et al reviewed 856 patients underwent extension
osteotomy for kyphosis and ankylosing spondylitis in 41
published articles. The overall neurological complication
was two to three percents. Four patients had aortic
rupture and ended up with mortality. All aortic ruptures
happened in the Smith-Peterson opening wedge
osteotomy group and the ruptures were attributed to the
opening up of the anterior column as the aorta is just
lying in front of the thoraco-lumbar spine, suggesting
this method is less safe compared with the other two
methods.5
Spinal Pseudarthrosis in Ankylosing
Spondylitis
This condition was first described by Romanus and Yden
in 1953. It appears as disco-vertebral destructive lesions
commonly in thoraco-lumbar junction in patients with
ankylosing spondylitis (Fig 8). Initially it was thought to
be caused by inflammation or infection of the spine. Fang
et al did en-block excision of the lesions in 35 patients for
histopathological analysis. They showed that the lesions
were fibrous tissue and/or fibrocartilage showing
fibrinoid necrosis and cystic degeneration characteristic
of pseudarthrosis.6 there are three possible causes for
formation of the pseudarthrosis. Firstly, the segment in
question may have escaped fusion while other levels
became ossified. The process of spinal ossification in
ankylosing spondylitis is multifocal and not contiguous,
so this process may leave short mobile segments between
long ankylosed segments. This set the scene for high
stress and mechanical failure. Secondly, there is a distinct
possibility of an acute fracture through an already fused
segment which ended up with non-union. Thirdly, the
mechanics of a stiff kyphotic spine result in high stresses,
especially near the thoraco-lumbar junction. Repeated
stress may lead to fatigue fracture as in stress fractures of
long bones. Both acute or stress fractures are predisposed
to non-union by the long level arm of the kyphotic
ankylosed spine.
Not all pseudarthrosis are symptomatic. In patients
whose lesions are painful, the pattern of pain may vary.
A patient with ankylosing spondylitis may present
initially with increasing pain and stiffness for a number
of years, and subsequently there is gradual decrease of
the amount of pain. A recent increase in pain or the pain
Surgical Interventions for Ankylosing
Spondylitis
Dr. WY Cheung
Department of Orthopaedics and Traumatology
Queen Mary Hospital, The University of Hong Kong.
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becomes more acute and perhaps more localised, may
suggest the development of pseudarthrosis. The second
pattern is noted in patients whose disease has already
burnt out so that there is no pain, but with residual
stiffness and deformity associated with a tiring posture.
The pain, which can recur, may be localised or more
acute. This also suggests development of pseudarthrosis.
Healing of the pseudarthrosis may rarely occur with
plaster cast or spinal brace immobilisation or without
any treatment. The indication for surgical treatment is
persistent and significant pain not responding to
conservative treatment. Another indication although
uncommon, is the presence of neurological symptoms.
Fang et al reported 18 lesions in 16 patients who
underwent anterior spinal fusion. Solid fusion was
achieved in 16 lesions. 15 patients had well to complete
relief of the back pain.7
Spinal fracture in ankylosing spondylitis.
Advanced ankylosing spondylitis creates a kyphotic, stiff
and brittle spine that is prompt to fracture. Most of the
spinal fractures involve three spinal columns
predisposing them to displacement and neurological
complications. Surgical stabilisation is usually indicated
to prevent neurological complications and allow early
mobilisation and rehabilitation. (Fig 9)
Hairline fractures can result in a patient with extensive
ossification of the spine. The fracture may occur as a result
of a fall or with very minor injury. In the process of trying
to break the fall, there is sudden and strong contraction of
paraspinal muscles resulting in a fracture. Hairline
fractures commonly occur at the cervicothoracic junction.
Plain x-ray may not reveal the fracture line. Clinical
suspicion together with marked tenderness may alert the
physician to such a problem. MRI and CT scan are more
sensitive in diagnosing the condition (Fig 10). Despite the
fracture is undisplaced, it is unstable and may result in
neurological injury if left untreated. Surgical fixation is
generally recommended in this condition.8
Ankylosing spondylitis with hip
involvement.
Apart from the spine, ankylosing may also involve the
hips. Total hip replacement is a well established treatment
for ankylosing spondylitis patients with severe hip
involvements. (Fig 11) The indications for surgery include
significant hip pain, stiffness and flexion deformity that
cause limitations in functions. Tang et al reported 96 total
hip replacements in 56 ankylosing spondylitis patients,
majority patients had good to excellent results.9 Joshi et al
reported 181 total hip arthroplasty in 103 patients with
ankylosing spondylitis. Ninety-six percent patients had
minimal or no hip pain and seventy percent of patient had
well to excellent function after surgery.10
Conclusion
Surgical interventions are indicated in some patients
suffering from ankylosing spondylitis. The indications for
surgery include: Firstly, severe kyphotic deformity, which
corrective spinal osteotomy can improve function and
decrease back pain. Secondly, patients with spinal
pseudarthrosis and back pain which failed conservative
treatment, spinal fusion can achieve bone union and
decrease back pain in majority of patients with this
condition. Thirdly, patients with spinal fractures, surgical
stabilisation can prevent neurological injury and allow
early mobilisation and rehabilitation. Fourthly, for
patients with severe hip involvements, total hip
arthroplasty can decrease hip pain and improve function.
Fig 1: Increased kyphosis shift the
centre of gravity anteriorly. More force
is required from the posterior back
muscles to maintain the up-right
posture.
Fig 2: A patient with ankylosing
spondylitis and severe kyphotic
deformity.
Fig 3: Smith Peterson opening wedge osteotomy.
Laminae and facet joints were taken down. Lordosis is achieved by closing
the posterior column and creating an opening wedge at the anterior column.
Fig 4: Thomason closing wedge osteotomy
Laminae, facet joints together with a wedge of the vertebral body are taken.
Lordosis is achieved by closing the anterior and posterior column.
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Fig 7: Cervico-thoracic kyphosis before and after surgery.3
Fig 8: Disco-vertebral destructive lesion at L1/2 compatible with pseudarthrosis.
Fig 6: Thoraco-lumbar kyphosis before and after surgery2
Fig 9: Fracture of lumbar spine in ankylosing spondylitis treated with
posterior instrumented fusion.
Fig 10: Hair-line fracture of cervical spine in ankylosing spondtlitis8.
Fig 5: Poly-segmental dorsal wedge osteotomy. V-shape laminae and facet
joints were taken at multiple levels. Lordosis was achieved by closing the
posterior column without opening up the anterior column.
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Introduction
Ankylosing Spondylitis (AS) is a chronic inflammatory
disease of unknown aetiology, characterised by
sacroiliitis and spondylitis. It typically affects the spine,
but other joints and organs are sometimes involved,
especially the hips. AS can be a severe disease and lead to
serious disability.
Medication, physical therapy and exercise are the main
stays of treatment.
For a long period of time, non-steroidal anti-
inflammatory drug (NSAID) was the only available
option for symptom alleviation in AS. In recent years,
however, considerable progress has been made in the
pharmacotherapy of AS. Anti-Tumour Necrosis Factor
(anti-TNF) agents had been shown to be highly effective
in controlling disease activity. Other medications that
may be useful include sulphasalazine, methotrexate,
pamidronate, thalidomide and intraarticular steroid.
Nonsteroidal Anti-inflammatory
Drugs (NSAID)
NSAIDs are effective in control of pain and stiffness in
AS patients. Indomethacin was once thought to be more
effective than the other NSAIDs. It is necessary to give
the maximum dose of 150mg to 200 mg per day in
divided doses. Incidence of side effects such as headache,
gastrointestinal upset and fluid retention are common.
One recent trial showed indomethacin and aceclofenac
were equally effective. Perhaps most NSAIDs in
adequate doses are equipotent. Different NSAIDs may
work best for different individual patients.
To assess the usefulness of a NSAID, it should be given
at a sustained dose on a regular basis for about two
weeks. After the maximum effect has been observed,
further use may be as needed for symptom control.
A recent study showed AS patients who were
continuously on NSAID were half as likely to develop
radiological progression when compared to those who
use NSAID on as needed basis. This made a suggestion
for continuous use of NSAID, regardless of the symptom
control. More large scale studies are needed to confirm
this observation.
COX2 inhibitors had been shown to be useful in double
blind controlled trials. Celecoxib 100 mg BD was found
to bemore effective than placebo. Etoricoxib (90mg/ day
or 120 mg/ day) was also found to be effective. Actually,
etoricoxib at this dose had been shown to be more
efficacious than naproxen 500 mg BD. Increase in
cardiovascular risk is a concern when COX2 inhibitor is
used for prolonged period of time though the actual
number of serious adverse cardiovascular events was small.
Tumour Necrosis Factor Alpha
Antagonists
Etanercept, infliximab and adalimumab are anti-TNF
agents that are commercially available. Both etanercept
(25mg sc twice weekly) and infliximab (5 mg/ kg infusion
at week 0, 2, 6, 12, 18) had been shown to be very
effective in AS in double blind placebo controlled
studies. Results of adalimumab trials are expected to be
published soon. Preliminary data suggest anti-TNF
agents can reverse bone marrow changes shown on
magnetic resonance imaging (MRI) and prevent
progression of radiological spinal changes as well.
However, potential side effects such as the increased risk
of pyogenic infections, reactivation of latent tuberculosis
and rarely development of lymphoma, should be
considered when using these agents.
The very high cost of anti-TNF therapy is a major
impediment to their widespread use and different
countries have different guidelines for its usage.
To put AS patient on anti-TNF therapy, they should meet
the following criteria:
1. Firm clinical diagnosis of AS
2. Active disease
The Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) is one common tool used by
rheumatologists to assess the disease activity of AS
patients.
3. Exclusion of contraindications
Active infections
Untreated latent tuberculosis
Demyelinating disease (eg. Multiple sclerosis, optic
neuritis )
Heart failure
Pregnancy and breast feeding
AS response rate to an anti-TNF agent is up to 80 percent
and the response is typically rapid, usually within six
weeks of treatment. Positive predictors of response to
TNF blockade include
Young age
Shorter disease duration
Good functional status, as measured by the Bath
Ankylosing Spondylitis Functional Index (BASFI)
Elevated ESR and C-reactive protein
Update in the Management of Ankylosing
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Sulphasalazine
There had been many trials on the usefulness of
sulphasalazine (SSZ) in AS. The trial with the largest
sample and that with the longest treatment duration
produced similar results. SSZ had benefit in subset of AS
patients with peripheral arthritis. Across all AS patients,
SSZ demonstrated some benefits in reducing ESR and
easing morning stiffness, but no significant improvement
in physical function, pain, spinal mobility, enthesitis,
patient and physician global assessment. The literature
concluded that patients at early disease stage, with high
level of ESR (or active disease) and peripheral arthritis
might benefit from SSZ but not those with only
symptoms and signs of axial disease.
Methotrexate
Methotrexate (MTX) is one of the most widely used
disease modifying anti-rheumatic drugs in the treatment
of Rheumatoid Arthritis. However, there is uncertainty
in its usefulness for treating AS.
A 2004 systematic review of the effectiveness of MTX in
AS found no evidence of benefit. However only two
studies met criteria for inclusion and these studies used
relative small doses of MTX (7.5 and 10 mg weekly
respectively). Furthermore , there were only a total of 81
patients in these two studies. More well designed
randomised controlled trials with sufficient patient
number and study duration , perhaps with higher dosage
regime as well, are needed to establish the role of MTX in
the treatment of AS.
Pamidronate
Because of some evidence of anti-inflammatory activity,
pamidronate has been evaluated in the treatment of AS.
In a double blind RCT, 84 patients with active AS despite
NSAIDs were randomised to pamidronate infusion 60mg
monthly or 10 mg monthly each for a period of 6 months.
The decrease in BASDAI was significantly greater with
the higher dose therapy. Pamidronate appears to be an
option when other medications are not feasible or useful.
Thalidomide
One abstract reported an open study of thalidomide (200-
300 mg per day) in 30 patients. After one year, 80 % of
patients had improved more than 20 % in 4 of 7 clinical
outcome measures (BASFI, BASDAI, early morning
stiffness, total body pain score, spinal pain, patient global
and physician global assessment). Well defined, controlled
studies are needed to define the role of thalidomide in the
treatment of AS. The cutaneous and neurological adverse
effects are of concern in its long term usage.
Steroid
Long-term systemic steroid is not recommended for AS
patient. Intraarticular steroid for peripheral arthritis and
local injection to painful plantar fasciitis can be helpful.
Injection of long acting steroid to sacroiliac joint may be
beneficial to patients unresponsive to other measures.
Physical therapy and exercise
It has been demonstrated that supervised group and
individual physical therapy can lead to symptomatic
relief and significant improvement and maintenance of
spinal mobility. An initial evaluation and treatment by
physical therapist should be part of every therapeutic
regimen. Physical therapy involves postural training,
range of motion exercises, and hydrotherapy. All AS
patients should be advised on regular specific home
exercises . In addition, pain relief measures such as local
heat or cold can be tried.
Conclusion
Recent advances in our understanding of ankylosing
spondylitis and the availability of potent therapeutic
options call forth a change from the traditional approach
to the management of the disease. Primary care
physicians and specialists alike should adopt an
expeditious rather than an expectant approach in the
diagnosis, referral and treatment of patients suffering
from ankylosing spondylitis in order to prevent
irreversible functional disability.
Clinic for Lease
Existing GP tenant with strong
client base is retiring in end
October in high growth area -
corner shop of Third
Street/Center Street, 100m to
proposed Sai Ying Pun MTR
station and Center Street
Escalator and new residential
complex. 800 sq ft with extra
storage area. See
www.cartebo.com/clinic for
details and contact
pinky.lui@cartebo.com or
9059-9228 after 2pm.
VOL.11 NO.5 MAY 2006 Medical Bulletin
17
L. 1 NO.11 NOVEMBER 2006
Introduction
Juvenile Idiopathic Arthritis(JIA) is the most common
form of chronic rheumatic disease in children. There is
wide variation in the epidemiological studies of JIA in
different countries. It is estimated that the overall
prevalence of JIA is from 0.07 to 4.01 per 1000 children.
From most outcome studies of JIA, active disease often
persists into adult life in all subtypes of JIA. Several
long term studies conducted from 1960s to 1990s
showed that 31% to 55% patients with JIA have active
disease when followed for at least 10 years.
Persistently active disease is associated with poor
outcome and long term disability. Thus, the current
management of JIA is to diagnose early, treat early and
be aggressive earlier in order to limit permanent
disability. This article focuses on the current medical
therapies of JIA.
Definition
JIA is defined as presence of arthritis (swelling or
effusion, limitation of range of motion, tenderness or
pain on motion, and increased heat) in one or more
joints. The age at onset is less than 16 years old. The
duration of arthritis lasts for 6 weeks or longer and
other causes of arthritis (e.g. septic arthritis,
malignancy) are excluded.
Classification
JIA is a new ILAR (International League Against
Rheumatism) classification of juvenile arthritis. (Table 1)
Treatment
A. Multi-disciplinary Approach
A coordinated multi-disciplinary team care consisting
of paediatric rheumatologist, nurse specialist, social
worker, physical therapist, occupational therapist,
orthopaedic surgeon and clinical psychologist is the key
to success of management of JIA. Uveitis is an
important extra-articular complication in children with
JIA. Children with JIA should have regular slit-lamp
screening by ophthalmologists. The aims of treatment
are to preserve cartilage, control pain and preserve
range of motion, muscle strength and function; to
manage systemic complications; to facilitate normal
nutrition, growth, and physical and psychological
development.
B. Medical Therapy
Non-steroidal Anti-inflammatoryMedications (NSAIDs)
Traditional NSAIDs are the first line therapy for all types
of JIA. Naproxen is effective in management of joint
inflammation in a dose of 15-20 mg/kg/day in two
divided doses. Other NSAIDs include ibuprofen (35
mg/kg/day in 4 divided doses), tolmetin (25-30 mg/kg/
day in 3 doses) and diclofenac (3-5 mg/kg/day in 4
doses). Other NSAIDs have specific indications but are
not officially approved for use in children.
Disease Modifying Anti-Rheumatic Medications
(DMARDs)
a. Methotrexate (MTX)
Methotrexate remains the remission-inducing agent of
first choice for persistent and active arthritis. Most
paediatric rheumatologists will initiate methotrexate
therapy early in the disease course, sometime within 8
weeks of initiation of NSAID therapy. The starting dose
is usually 15 mg/m2/week per oral route. Daily folic acid
supplementation (1 mg/day) may alleviate the side
effects of nausea, vomiting, gastrointestinal upset and
mucosal stomatitis without compromising the
therapeutic effect. If the response is inadequate, it could
be stepped up with an increment of 2.5 mg/week.
Subcutaneous route is advised if the dose reaches 20
mg/week or more.
Most studies have demonstrated no severe liver damage
in children taking methotrexate for extended periods.
There is no clear evidence that methotrexate increases the
risk of malignancy in children. In our hospital, a
retrospective study (from 1996 to 2005) of 40 children
with JIA was performed to review the treatment outcome
and adverse effects associated with use of MTX. We
concluded that MTX was safe and well tolerated in the
majority of patients, but treatment response varied with
different JIA subtypes. Methotrexate is teratogenic and
adolescent patients are advised about prevention of
pregnancy and total abstinence from alcohol drinking.
Patients should be informed of the nature, toxicities,
precautions, expected duration of therapy and education
of subcutaneous injection technique.
b. Leflunomide
Methotrexate is the mainstay of therapy, but recently,
combination DMARD therapy such as methotrexate and
leflunomide has been shown to have better clinical
outcomes when methotrexate monotherapy fails.
Headache, diarrhoea, abdominal pain, elevated liver
enzymes, reversible hair loss and skin rash are the reported
side effects. Leflunomide is teratogenic and patients should
not take alcohol tominimise hepatotoxocity.
Current Management of Juvenile Idiopathic
Arthritis
Dr. Tsz-leung Lee
Associate Consultant
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong,
Queen Mary Hospital, Pokfulam, Hong Kong, China
Dr. Tsz-leung Lee
MRCP(UK), FHKAM
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i. TNF Inhibitors
Etanercept, a TNF receptor antagonist, is the first
biologic to be approved by the FDA for use in JIA. In
a randomised, prospective, placebo-controlled trial in
children who had severe JIA not controlled by
methotrexate, etanercept induced a rapid, significant
improvement in the clinical and laboratory features
of JIA. The median improvements ranged from 40%
to 95%. Etanercept is well tolerated in children, with
headache, upper respiratory tract infections, and
injection site reactions being the toxicities reported
most commonly. Rare but serious infections such as
sepsis and varicella meningitis have been reported.
Other infections, such as TB, histoplasmosis, and
listeriosis, have been reported in people taking anti-
TNF-alpha drugs. Neurologic disorders, retrobulbar
optic neuropathy, cutaneous vasculitis, and
pancytopenia have been reported. Data on the long-
term toxicity of etanercept are not available. Other
anti-TNF-alpha biologics such as infliximab and
adalimumab have been given to children who have
JIA, with improved response.
ii. Anti-IL 6
Anti-IL-6R, termed tocilizumab, has been tried in
children who had systemic arthritis with some
success.
iii. Anakinra
i. Anakinra is a recombinant form of agonist to
interleukin-1 receptor (IL-1Ra) and its use in arthritis
treatment is associated with reduction in mononuclear
cell infiltration of the synovial membrane. A few
anecdotal reports indicate good responses to the use of
anakinra ( IL-1 receptor antagonist) in JIA.
c. Corticosteroid:
Systemic Corticosteroid
Moderate or high dose systemic corticosteroid therapy
should be reserved for patients with systemic arthritis
with severe systemic symptoms that cannot be
controlled with NSAID, such as macrophage activation
syndrome, symptomatic serositis and myocarditis.
Systemic corticosteroid is not recommended for all
other subtypes of JIA.
Intra-articular Corticosteroid Injection
Intra-articular corticosteroid is a safe and effective
treatment in managing synovial inflammation in a child
with monoarticular or oligoarticular arthritis. It is
sometimes indicated in treatment of particular
symptomatic joints in a child with polyarticular
arthritis. It provides sustained anti-inflammatory effect
on synovium lasting for 4 to 6 months in most cases. It
has been shown by magnetic resonance imaging studies
that intra-articular steroid therapy resulted in
significant suppression of inflammation and pannus
formation while cartilage integrity is well preserved.
d. Sulphasalazine (SSZ)
SSZ has been shown to be effective in children with
oligoarthritis or spondylitis at doses 30-50 mg/kg/day
(maximum dose 2000 mg/day). The adverse effects are
gastrointestinal intolerance, rash, leukopenia and
hypogamma-globulinaemia.
e. Cycloporine A (CsA)
There are no controlled trials on the use of CsA in JIA
treatment. A few open studies suggest that it may have
a role in the treatment of systemic symptoms of
systemic-onset JIA and steroid sparing effect but less
convincing efficacy for arthritis control. The usual dose
is 3-5 mg/kg/day. Adverse effects include hypertension,
hand tremor, impaired renal function, gingival
hyperplasia and hypertrichosis.
f. Combination DMARD Therapy
If conventional treatment with a single DMARD fails to
adequately control clinical symptoms or to prevent
disease progression, combination DMARD therapy is
indicated. In such cases, rheumatologist referral is
strongly recommended.
g. Biologic Agents
It has been shown that tumour necrosis factor and other
cytokines like interleukin 1 and interleukin 6 are
important mediators of joint and synovial
inflammation. Targeted monoclonal antibody therapies
have been developed recently.
h. Thalidomide
1. Thalidomide is a potential agent that looks
promising in treatment of inflammatory joint disease.
C. Autologous Stem Cell Transplantation (ASCT)
Despite the emergence of new therapeutic agents
which appear to be more effective in treating JIA, there
are still some patients who remain resistant to medical
therapies. Autologous stem cell transplantation has
been considered in recalcitrant cases. Drug-free
remissions of disease have been reported, but the
procedure carries a significant mortality risk, usually
from macrophage activation syndrome. Stem cell
transplantation should be performed only after all
other treatment options have failed. In our hospital,
we have performed autologous stem cel l
transplantation for two patients. One is in complete
remission with follow up more than 6 years and the
other relapsed 9 months after transplantation, and
remission is achieved with combination therapy of
leflunomide, cyclosporine and thalidomide. At
present, this treatment should be considered
experimental and should be reserved for those patients
who have most severe disease unresponsive to
standard treatment.
Conclusion
Progress in achieving international consensus
concerning the classification of JIA has been made.
There are many promising developments in the
understanding and improved treatment options in JIA.
In order to prevent long term disability, earlier and
more aggressive therapy is advised for those with
persistent arthritis. A multidisciplinary team approach
is very important in management of JIA. It is hoped
that with increased awareness of the long term
morbidity of JIA and the availability of new treatment
options in JIA, the outcome of patients with JIA could
be further improved.
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Systemic arthritis
Oligoarthritis
o Persistent
o Extended
Polyarthritis (*RF-negative)
Polyarthritis (*RF-positive)
Enthesitis-related arthritis
Psoriatic arthritis
Other
Arthritis
daily fever for at least 2 weeks
evanescent nonfixed erythematous rash
generalised lymphadenopathy
hepato/splenomegaly
serositis.
Arthritis of one to four joints during the first 6
months of disease.
Affects no more than four joints throughout the
disease course.
Affects more than four joints after the first 6
months.
Affects five or more joints in the first 6 months of
disease. Tests for RF are negative.
Affects five or more joints in the first 6 months of
disease.
Arthritis and enthesitis or arthritis or enthesitis
with at least two of:
sacroiliac tenderness and/or inflammatory spinal
pain,
human leukocyte antigen (HLA) B27-positive,
family history in a first- or second-degree
relative of medically confirmed HLA B27-
associated disease.
Arthritis and psoriasis or arthritis and at least
two of:
dactylitis,
nail abnormalities,
family history of psoriasis in at least one first-
degree relative.
Arthritis of unknown cause persisting for at least
6 weeks that either does not fulfill criteria for
any categories or fulfills criteria for more than
one category
Table 1 ILAR Classification of JIA
Petty RE, Southwood TR, Baum J, et al. Revision of the proposed
classification criteria for juvenile idiopathic arthritis: Durban,
1997. J Rheumatol 1998;25:1991-4.
Schneider R, Passo MH. Juvenile rheumatoid arthritis. Rheum Dis
Clin North Am 2002;28:503-30.
Ellen A. Goldmuntz, Patience H. White. Juvenile Idiopathic
Arthritis: a review for the pediatrician. Pediatrics in Review Vol 27
No.4 April 2006 c24-c32
PPW Lee, TL Lee, WHS Wong, YL Lau. The use of methotrexate
in juvenile idiopathic arthritis: a single center experience. HK J
Paediatr (new series) 2006;11:191 -198
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* RF=rheumatoid factor
The Medical and Dental Directory of
Hong Kong - new 8th Edition
Call for submission of individual data from all medical and
dental practitioners
To all medical and dental practitioners,
We would like to take this opportunity to invite you to send us your most up-to-
date information. You can complete the form and return to us by facsimile,
through mail or via our Federation's Home Page: www.fmshk.org/directory . All
respondents will be entitled to a free copy of the Medical & Dental Directory of
Hong Kong 2007 upon submission of data. A voluntary contribution of HK$100 or
above is welcome and upon submission, a data CD and Directory will be sent to
your office (includes postage and package), otherwise you may have to pick up the
Directory from the Federation office yourself if no contribution is made. In case we
do not hear from you, basic information will be extracted from the available records
of the Medical Council of Hong Kong and the Dental Council of Hong Kong. Thank
you for your co-operation.
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Ended with tragic side effects & revived
for desperate conditions
Thalidomide was synthesized in 1954 and prescribed as a
sedative, tranquiliser, and anti-emetic for morning
sickness. It is chemically similar to barbiturate, but with
much less hang-over, and thus soon became very popular.
However, after the emergence of reports of teratogenicity,
in particular foetal limb malformation, including pregnant
women who took as little as a single dose of the drug, it
was withdrawn from the European and Canadian markets
in 1961 - 62.
A few years later, an Israeli physician administered some
old supplies of thalidomide to a patient with leprosy and
mania for sedation. Surprisingly, it gave dramatic and
near complete resolution of the patient's cutaneous
symptoms. However, it was not until the discovery to
thalidomide's anti-tumour necrosis factor-　(TNF　)
activity in 1991 and experimental evidence of its ability to
interfere with vasculogenesis in 1994 that interest in re-
emergence of the drug was rekindled. Now it has been
extensively studied for use in many refractory malignant
or inflammatory conditions.
Between nasty poison and last card -
immunomodulatory action
The immunomodulatory effects of thalidomide are
complex and incompletely understood. Its key ability is to
inhibit the production of TNF , primarily on monocytes
and also T-lymphocytes, alveolar macrophages, lamina
propria mononuclear cells and microglial cells. How
thalidomide inhibits TNF production remains unclear
but it seems to involve the enhancement of TNF mRNA
degradation and inhibition of NF (nuclear factor)-KB
activation. Besides its effects on TNF production,
thalidomide can also enhance the production of IL
(interleukin)-4 and IL-5, while inhibiting IL-12 production.
It also acts as a T-cell co-stimulant, which is potentially
beneficial to anti-tumour activity. Moreover, it is capable
of inhibiting angiogenesis induced by vascular endothelial
derived growth factor and basic fibroblast growth factor.
Themolecule
Thalidomide is a derivative of glutamic acid. It is
administered clinically as a 1:1 racaemic mixture of S and
R enantiomers (mirror image isomers) that interconvert
under physiological conditions. It is well absorbed after
oral administration, eliminated by spontaneous
hydrolysis to multiple chemically inactive metabolites,
and has a half-life of around five hours.
Recent convert of an ex-convict
Thalidomide is particularly useful in treatment of
mucocutaneous diseases. Erythema nodosum leprosum
was the first approved indication by Food and Drug
Administration of the United States. Resistant oral
aphthous ulceration, whether idiopathic or associated
with human immunodeficiency virus infection, and the
granulomatous skin lesions of sarcoidosis all respond
very well to thalidomide.
Another major application of thalidomide is in
haematological malignancies. The most promising results
to date have been in the treatment of multiple myeloma.
Up to 35% response rate in refractory cases had been
reported. Thalidomide can also be useful in high-risk
myelodysplasia, acute and chronic myeloid leukaemia,
and other myeloproliferative disorders. In contrast, the
efficacy of thalidomide in solid organ tumours is less
well documented, because increased thromboembolic
disease has also been reported. Thalidomide has also
been reported to be beneficial in Crohn's disease, wasting
and cancer cachexia.
Use of thalidomide in rheumatic
diseases
In non-randomised studies, thalidomide was moderately
effective for the treatment of refractory cutaneous
lesions of lupus, which otherwise had inadequate
response to treatment with anti-malarial agents, steroid
or other immunosuppressive drugs. Overall, clinical
response rates ranged from 84% to 100% at daily doses of
50 - 400 mg, with the possibility of subsequent
maintenance therapy after initial response. The effects of
thalidomide on visceral and articular involvement of
lupus are conflicting. In short, thalidomide is considered
second-line therapy in cutaneous lupus, as its usefulness
is mainly limited by potential neurotoxicity and extent of
relapse after discontinuation of therapy.
Ankylosing spondylitis, a chronic inflammatory disease
of axial skeleton (spine and particularly sacroiliiac joints)
and occasionally other peripheral joints, also shows good
response to thalidomide. An open-label study was
conducted in Mainland China which involved 30 male
patients suffering from severe and active ankylosing
spondylitis refractory to non-steroid anti-inflammatory
Use of Thalidomide in Rheumatic Diseases
For the vast majority who won't start it
Dr. Moon-ho Leung
Associate Consultant, Department of Medicine, Queen Elizabeth Hospital
Dr. Moon-ho Leung
MBBS, MRCP, MSc(Rhu)(Birm), FHKCP, FHKAM (Medicine)
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drugs, sulphasalazine, methotrexate and even
corticosteroid. Thalidomide 200 mg daily was used. As a
result, 80% of the 26 patients who completed the study
experienced at least 20% improvement in the functional
and disease indices. Prompt improvement was noticed at
3-6 months. Nine patients (30%) became pain-free.
Decreased expression of several pro-inflammatory genes,
including TNF and IL-1 in peripheral blood mononuclear
cells from these patients after thalidomide treatment was
also noted. The common side effects in this study were
slight drowsiness and dry mouth, and these gradually
subsided upon continued treatment. Only one patient in
this study stopped thalidomide at 12th month because of
tingling sensation over fingers for few seconds daily
lasting for three days.
Behcet's disease is an inflammatory disease of unknown
aetiology characterised by episodic exacerbation of oral
ulcers, genital ulcers, uveitis, arthritis, erythema nodosum
and other skin lesions. Several uncontrolled studies have
shown that thalidomide is effective in both treatment and
prevention of recurrence of orogenital ulceration in
Behcet's disease. In a placebo controlled trial, oral and
genital lesions of Behcet's disease improved after
treatment with thalidomide (100mg or 300mg) versus
placebo, with complete response rates of 9% on treatment
versus 0% on placebo. Typically, oral lesions healed in 3 - 4
weeks, but recurrences were common after stopping the
drug. Despite its effectiveness in orogenital ulcers,
thalidomide appears to offer little help on uveitis in
Behcet's disease.
For some unclear reasons, the effect of thalidomide is not
so impressive in refractory rheumatoid arthritis, a chronic
inflammatory arthropathy mediated in part by TNF .
Thalidomide has also been tried, but without major
success, in a limited number of patients suffering from
other rheumatic diseases such as Still's disease,
scleroderma and Sjogren's syndrome.
Side effects
Thalidomide is notorious for being extremely teratogenic.
In utero exposure of the drug, with even a single 50 mg
dose taken in first trimester, could cause 10% - 50% risk of
birth defects. Common foetal abnormalities are
phocomelia (short limbs) or amelia (absent limbs), central
skeletal or craniofacial abnormalities and visceral
malformation. The mechanisms of teratogenicity may
involve free radical mediated embryonic DNA oxidative
damage, and disturbed cellular recognition through
interaction with adhesionmolecules.
Peripheral neuropathy is the next serious side effect and it
occurs at a rate ranging from 1% to 70% in different series,
depending on whether it is documented on clinical
ground or with more sophisticated electrophysiological
studies. Age and cumulative dose were identified to be
associated factors in a large prospective study, though not
so in another retrospective study. Typical presentation is
painful or burning sensory neuropathy in association with
mild proximal myopathy. Upon cessation of thalidomide,
weakness rapidly resolves but sensory changes are usually
slow to recover and in some cases may be irreversible.
Other side effects include somnolence (ironically the
originally intended "effect"), constipation, dizziness,
macular rash, decreased libido and rarely neutropenia.
Taming the shrewd - Precautions
Thalidomide should only be used to treat severe disabling
conditions refractory to conventional treatment. In many
public hospitals and clinics, the drug is available on a
named patient basis. Patients should be encouraged to
take part in the decision making process of resorting to
thalidomide therapy. They should be well informed to
consider such major undertaking , by striking the balance
between possible benefit of controlling a refractory disease
versus potential side effects and the absolute willingness
to prevent pregnancy.
Any women of childbearing potential must be aware of
the risk of birth defects and they should have a negative
pregnancy test done shortly before starting thalidomide.
They must abstain from intercourse or use two forms of
contraception at the same time, which must begin one
month before starting thalidomide and continued for at
least one month after stopping treatment. Male patients
must use a condom every time they have intercourse, even
if they have undergone vasectomy.
Baseline nerve conduction studies may be useful, and
patient should be advised to stop thalidomide should any
neuropathic symptom arise. Bedtime dosing can minimise
the side effect of somnolence.
The case for a special role in Asia
Roughly speaking, thalidomide can be regarded as an oral
anti-TNF agent, and supposingly less expensive than
biologic agents specfically designed for such purpose.
Indeed, anti-TNF therapy is currently the breakthrough
for treating refractory ankylosing spondylitis. However,
TNF is also a key cytokine in the body's defense against
infection. Sepsis, including active tuberculosis, is a
contraindication to anti-TNF treatment. Chronic hepatitis
carriers were excluded from clinical trials on use of anti-
TNF agents in refractory ankylosing spondylitis in
western countries, as there were reported cases of fatal
hepatitis C exacerbation after such treatment. There are
only scattered reports on the safety of thalidomide use in
hepatitis B and hepatitis C carriers in the literature. Here is
the tantalising question - Is thalidomide a "safer" anti-
TNF agent in concomitant tuberculous infection and
chronic hepatitis carriers? More intriguing is whether
thalidomide can be a temporary substitute for biologic
agents, the cost of which is certainly prohibitory.
Conclusion
Thalidomide has been demonstrated to be useful in some
rheumatic conditions such as cutaneous lupus, ankylosing
spondylitis and Behcet's disease when conventional
treatment fails. However, contraception must be faithfully
exercised, as teratogenicity remains the ultra concern.
Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the
wilderness. Postgrad Med J 2003;79:127-132
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thalidomide in the treatment of lupus. Lupus 2001;10:188-92
Huang F, Gu J, Zhao W, et al. A one year open label trial of thalidomide in the
treatment of refractory ankylosing spondylitis. Arthritis Rheum 2002;47:249-54
Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the
mucocutaneous lesions of the Behcet syndrome. A randomized, double-
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Clinical Quiz
Dr. WendyWM Lam
Consultant, Department of Radiology, QueenMary Hospital
Clinical History
Radiological Findings:
1) Generalised bone sclerosis
2) Multiple lytic lesions over the pelvic bones
3) Lytic lesions over both proximal femoral shafts with
endosteal scalloping
M/53
C/O Bone Pain
XR Pelvis for comment
Doctor Vacancies
Dentist Vacancies
Office Vacancies
For Sale
(flat, car, office, etc.)
Please contact the Federation Secretariat at 2527 8898 for placement of classified advertisement.
( Charge: HK$ 600 per 30 word unit, HK$50 per additional 10 word unit)
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Having just completed Basic Physician Training
requirements in Medicine at the Queen Mary Hospital, I
was able to sit back and relax, contemplating on what to
do with my limited free time. As an avid sports
enthusiast, I spend most of my time after work with
outdoor sports and family commitments.
Following along the footsteps of my father, I have
learned to appreciate the game of golf since the age of 8.
Although there aren't many places to play in Hong
Kong, golf as a serious - and often expensive - hobby
has become my pride and joy. I practise regularly at
any driving range I can find, and travel up to the
Mainland for the infrequent game of golf with peers or
relatives. My goal is to achieve a handicap (card) and to
play in golf courses elsewhere in Asia. Golf advice on
staying fit: avoid golf carts, carry your own clubs.
On the contrary, a much cheaper alternative is to
pursue one of the leisure trailwalking excursions in
Hong Kong. As a doctor with a borderline high-normal
BMI, I feel that there is no excuse for "no time for
exercise". I like to hike, in groups or alone, in rain or in
sun. The breath of fresh air re-invigorates me and
allows me to capture a glimpse of what Hong Kong's
natural beauty has to offer. Hiking and trail-walking is
both mentally and physically challengingat times.
I was able to knock off 6 pounds of extra weight just
from trailwalking alone. Trailwalking advice on
staying fit: if you walk and your long-range pager has no
s igna l , you have probab ly walked enough.
To water sports. Be it swimming, wakeboarding or
diving, water sports are another area of interest of mine.
I frequently venture out to the remote areas of Sai Kung
to swim, dive or wakeboard. Although Hong Kong's
weather can be very temperamental, these activities
reiterate one thing - outdoor activities are truly fun and
exciting. As I have yet to tear a ligament or fracture a
bone, I will continue to try wakeboarding as much as I
can. Diving advice on staying fit: wakeboarding is fun as
long as you don't try tricks.
As I continue to try and find time to enjoy these
activities, I am compiling a book with many
photographic scenes on Hong Kong's untapped
outdoors. From the remote and abandoned villages in
the New Territories to the little idyllic islands off the
Mainland, there are so much to see and so much to
do. So to stay fit and rejuvenated, get away from the
hustle of city life and put your body to the test. And
if you are going to sit there and remain sedentary all
your life, then you will regret what you are missing
out on...
On Staying Fit
Dr. Axel SJ Hsu
Department of Medicine, Queen Mary Hospital
Dr. Axel SJ Hsu
BSc, MBBS, MRCP
MULTIPLE MYELOMA
Answer to Clinical Quiz
Dr. WendyWM Lam
Consultant, Department of Radiology, QueenMary Hospital
Diagnosis:
Classical multiple myeloma most commonly appears as multiple osteolytic lesions scattered throughout the skeletal system,
particularly in the vertebrae, skull, ribs and pelvis. It is rarely osteoblastic.
Bone sclerosis is a rare primary roentgenographic manifestation of myeloma (1-3%) and may occur as a sclerotic margin
surrounding a lytic lesion, an increase in bony trabeculation or a diffuse sclerosis. Sclerosis sometimes occurs after
chemotherapy, radiotherapy or fluoride administration, and also when the myeloma is complicated by fracture, amyloidosis or
Paget's disease.
Osteosclerotic myeloma is a rare variant, and the patients are usually younger and less sick, often with a peripheral neuropathy
and a more indolent disease course. They rarely complain of bone pain but rather the pain of peripheral neuropathy. Although
less than 5% of patients with multiple myeloma have neuropathy, 50% with osteosclerotic myeloma develop it, with or without
associated findings of organomegaly and endocrinopathy. The POEMS syndrome consists of a plasma cell dyscrasia with
polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes.
Discussion:
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Abstracts from the Federation's Annual Scientific
Meeting 2006 :
Stem Cells From Bench to Bedside
Neural Stem Cells: Basic and Clinical Studies
Dr. WutianWu
Department of Anatomy, LKS Faculty of Medicine, The University of
Hong Kong
Neural stem cells (NSCs) can be expanded and induced to
differentiate into neurons and glia, which provides a potential
therapeutic application for many neurodegenerative diseases
and brain injury, such as Parkinson's disease, brain ischaemia
and spinal cord injury. Transplantation of NSCs may replace
the loss of neurons and glia due to the above
neurodegenerative diseases. Although there have been several
clinical studies using NSCs or other cells for the treatment of
CNS diseases, several unsolved issues need to be addressed
before NSCs transplantation can be considered for the clinical
application. These issues include (i) the ideal NSCs source for
transplantation for a given neurodegenerative diseases, (ii) the
route of NSCs administration, (iii) the survival, differentiation
and persistence of NSCs in the targeted area, (iv) the integration
of transplanted NSCs with the host CNS. The present study
investigated the survival and differentiation of NSCs isolated
from embryonic or new-born CNS tissues in both in vitro and
in vivomodels. The potential application of NSCs in spinal cord
injury is discussed.
Use of "Adult Stem Cells" in Children: the
Current Status and Future Potentials
Dr. Godfrey CF Chan
Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital, The
University of Hong Kong
Human stem cells are known to have vast potentials in treating
human diseases. However, there are different kinds of stem
cells being studied or applied clinically. Some of them, such as
embryonal stem cells which can be prepared by nuclear transfer
technology, have the genuine multipotent differentiating
capacity but unfortunately, are restricted by the ethical and
legal boundary for clinical application. While adult stem cells,
which include haematopoeitic stem cells (HSCs), mesenchymal
stem cells (MSCs), neural stem cells etc., are not as versatile in
their differentiating ability but they are widely accepted for
clinical use.
Among adult stem cells, HSCs are the most extensively used
clinically. HSCs can be derived from bone marrow, cord blood
or mobilized peripheral blood. Previously, HSCs transplant are
confined to the treatment of haematological illnesses such as
leukaemia, marrow failure or thalassaemia. It can also serve as
a marrow support after megadose chemotherapy in selected
solid tumours treatment. In recent decade, HSCs have been
successfully applied to a wide range of non-haematological
inherited diseases including metabolic disorders, storage
diseases, primary immunodeficiency, bone disease (i.e.
osteopetrosis). In addition, chemotherapy + CD34 selected
autologous HSCs can now be used for many forms of poor risk
autoimmune diseases including scleroderma, multiple sclerosis,
Techniques of Cord Blood Collection
Dr. Dominic FH Li
Specialist in Obstetrics & Gynaecology
Since the first case of cord blood transplant was performed in
France on a boy with Fanconi's Anaemia in 1988, a lot of
interest was generated on Cord Blood Collection and
Transplantation around the world. Cord blood storage offers
expectant parents an once-in-a-lifetime opportunity to collect
and store their newborns' umbilical cord blood for potential
life-saving use in future. This can be considered as a unique
and highly innovative form of biological insurance. Cord
blood banking is a safe, simple and convenient way to provide
family members with insurance on life. Scientists recently are
aware that cord blood can be successfully used as alternative
to bone marrow for transplantation as cord blood is also rich
in stem cells. This can be used on the child himself or herself,
other family members (usually brothers and sisters who have
similar HLA make-up as the cord blood) or other unrelated
persons, children or adults, who are HLA-compatible with the
cord blood. Collection of cord blood is easy and there is
absence of risk to the donors (mother and newborn). There
are less viral contaminations e.g. CMV etc and lower risks of
rejection and GVHD. Incomplete HLA identity matching is
possible and there is the advantage of immediate availability.
The techniques of collection, processing and storage of cord
blood will be discussed.
"Stem Cells - From Bench to Bedside" -
Neurological Application
Dr. Gilberto KK Leung
Department of Neurosurgery, Queen Mary Hospital
The application of stem cell therapy in the treatment of central
nervous system disorders is a natural extension of the recently
developed concept of restorative neurology. Unlike
refractory SLE or JIA. The experience of our centre in applying
HSCs to these diseases will be discussed.
Recently, bone marrow derived MSCs emerged as another
important adult stem cells that can be applied to a wide
spectrum of clinical diseases. Since they can form bone,
cartilage, muscle and even cross lineage barrier into neurons
and hepatocytes, they are intensively studied for the
bioengineering purpose of replacing damaged tissues such as
degenerated disc/cartilage or infarcted heart muscle. In
paediatric setting, they have been tried for the treatment of
osteogenesis imperfecta. In addition to their differentiating
potential, they also have a potent immunosuppressive effect
and recently, MSCs have been used in treating refractory graft
versus host disease in organ transplant setting. Our laboratory
has been studying the biology of human marrow derived
MSCs for the past few years and some of the MSCs' unique
biological properties will be discussed.
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neuroprotection, which aims at minimising cellular injury,
the restorative approach is concerned with the restoration of
lost neuronal populations and functions by means of either
the induction of endogenous neurogenesis or the
implantation of progenitor neuronal stem cells. The latter
approach, so-called 'neurotransplantation', is a particularly
exciting field which has attracted a significant amount of
attention and research effort in recent years.
Conceptually, stem cell therapy may have potential roles in
the treatment of a wide range of neurological disorders,
including ischaemic cerebral infarction, head trauma, spinal
cord injury, brain tumours, and neurodegenerative diseases
such as Parkinson's disease. Experimental studies have
generated some promising results although many questions
are still unanswered. Despite the apparent functional benefit
observed in experimental animals following transplantation,
the exact fate and behaviour of the transplanted stem cells
are still unclear, and the mechanism by which
transplantation may confer benefit is poorly understood.
Practical issues such as the ideal cell source, the optimal
timing and location of implantation, the choice of patients,
and the role of immunosuppression are yet to be
determined. Safety issues including infection and
tumourogenicity of the implanted cells are other major
concerns. Available data so far have not demonstrated any
significant clinical benefit in human subjects.
In this review, the author aims at providing an overview of
the recent development in stem cells therapy for the
treatment of neurological disorders.
Stem Cell Therapy in Cardiovascular Diseases
Dr. Hung-fat Tse
Department of Medicine, the University of Hong Kong, Queen Mary
Hospital
Despite the major efforts to prevent and treat cardiovascular
diseases, they remain the most common cause of death in the
western world and China. The main culprit is congestive
heart failure, which can be caused by myocardial infarction,
hypertension or any other insults to the heart. Human heart
loses most of their regeneration capacity in the postnatal
development, and is not able to replace any defects after
damage to the myocardium. Currently, the only available
curative therapy for patients with end-stage heart failure is
heart transplantation, but is limited by the severe shortage of
donor organs and transplant rejection. Stem cell
transplantation has been explored as potential therapy to
limit the progression of heart failure. Our recent clinical
studies have highlighted the potential capacity to regenerate
new blood vessels for the heart by intramyocardial injection
of bone marrow stem cells. However, due to the limited
developmental plasticity of these adult bone marrow stem
cell, this approach may not be sufficient to replace
cardiomyocyte (CM) loss due to heart attack. Direct CM
replacement therapy is an obvious and promising option but
is also limited by the availability of transplantable human
CMs. Human embryonic stem cells (hESCs), isolated from
the inner cell mass of human blastocysts, can propagate
indefinitely in culture while maintaining their pluripotency,
including the ability to differentiate into CMs; therefore,
hESCs may provide an unlimited ex vivo source of CMs for
transplantation and other cell-based therapies. In
combination with recent advances in biomedical engineering
techniques, hESCs have therefore enabled researchers to
pursue the revolutionary paradigm of regenerative medicine
for repairing, replacing or enhancing organ function in such
aging-related diseases as heart failure.
Ethical Considerations of the Uses of Human
Stem Cells
Prof. Edwin C Hui
Medical Ethics Unit, LKS Faculty of Medicine, The University of Hong
Kong
The ability to produce and culture pluripotent human stem
cells has created a brand new field called regenerative
medicine whereby tissues that are previously considered to
be without the capacity to regenerate themselves when
damaged, notably the brain and the heart, can now be
replaced by stem cells coaxed to become the damaged
tissue. This has raised hope for those with terminal heart
disease, Parkinson's disease, multiple sclerosis, spinal cord
injuries and others. But at the same time, the use of human
stem cells has also sparked intense debate in different
countries as well as in the international scene. For all
practical purposes, there are five different sources of
human stem cells, and only two are ethically controversial
as their derivations entail the destruction of human
embryos. At the same time stem cells from the inner cell
mass of the embryo are most potent. When cultured in the
proper medium, these cells can multiply indefinitely as
immortal cells; or under proper coaxing conditions they can
be directed to become any one of the 220 cell types of the
human body. There are 3 different sources of human
embryos available for stem cell harvesting, and the moral
assessment for each is significantly different. These include:
(1) 'surplus' embryos following in vitro fertilisation (IVF)
for infertility treatment; (2) embryos created through IVF
specifically for the purpose of harvesting stem cells; (3)
embryos created through somatic cell nuclear transfer (NT)
specifically for the purpose of harvesting stem cells. The
two other sources of stem cells whose derivations are
unrelated to the destruction of embryo are (1) stem cells
from "adult" somatic tissues including the bone marrow,
adipose tissue, central nervous system, muscle, placenta
and umbilical cord blood, and (2) stem cells from primitive
foetal gonadal tissues (foetal germ cells). There is a rough
hierarchy of contentiousness ordering the different ways of
producing human stem cells, and in the order of decreasing
degree of contentiousness: (1) embryonic stem cells created
by NT; (2) embryonic stem cells from embryos specifically
created for stem cell harvesting; (3) embryonic stem cells
from 'surplus' embryos; (4) foetal germ cells; (5) adult stem
cells. This paper discusses the ethical considerations for
different sources of stem cells and some public policy
concerns they raise.
Intervertebral Disc Regeneration
Prof. Kenneth MC Cheung
Division of Spine Surgery, Department of Orthopedic Surgery, The
University of Hong Kong
Intervertebral disc degeneration and its consequences is a
highly significant cause of low back pain and sciatica.
Current treatment for severe back pain usually involves
fusion of the spine, while more experimental procedures,
such as replacement by an artificial intervertebral disc may
have a role.
However a biological solution would be more ideal and
considerable research work has been carried out in this area
by our Division as well as others.
This presentation will provide an overview of the current
science, and outlines where the likely future advances
will be.
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Unrelated Stem Cells Source
Dr. Cheuk-kwong Lee
Hong Kong Red Cross Blood Transfusion Service
Stem cells are primal undifferentiated cells that retain the
ability to divide and differentiate into other cell types. They
have been the focus in clinical medicine for the past few
decades because of the potential to change the face of human
disease by being used to repair specific tissues or to grow
organs.
At present, the most common and clinically proven
application is on the use of haematopoietic stem cells (adult
or cord blood) for bone marrow transplantation which has
shown an exponential growth in the number of procedures
performed in the last two decades. Moreover, since the
millennium, exciting reports also appeared on the
applications of stem cells in clinical conditions like
Parkinson's disease, myocardial infarction/ heart failure and
spinal cord damage.
Although it is now known that we are able to isolate and
obtain stem cells from other tissues such as human embryo,
oocytes and adipose tissue, the present discussion will limit
to unrelated haematopoietic stem cell source for bone
marrow transplantation only. In Hong Kong, the Blood
Transfusion Service is the organisation providing such
service. A centralised cord blood bank was established in
1998 whereas Hong Kong Bone marrow Donor Registry has
started its service since 1 September 2005 on donor
recruitment, searching, and co-ordination of haematopoietic
stem cell donation.
Safety of donation, donors and recipients remains the most
important concern. In the unrelated setting, the donation risk
should always be minimal to the voluntary non-remunerated
donors whereas the transplantation risk should be acceptable
to the recipient. Therefore, it appears to have a need of
consensus on requirement of stringent donor eligibility and
quality control on the collection, testing and storage and
their applications. Lastly, one should not overlook the
importance in ethical consideration of recruitment, donor
confidentiality in searching, matching and donation and of
course their clinical uses.
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Soccer Five Tournament 2006
Match results for 23 September 2006
Match on 23 September 2006
There were 4 exciting matches between pharmaceutical companies
on 23 September 2006. All teams played well with support from
their friends. GSK team from back row left to right: Jocky Chan, Shek,
Nixon Nip, Anthony Ho, Keith Cheng, front row left to
right: Gary Chan, Ricky Wan, Wilson Yuen, Garick Ho
GSK
Sanofi-Aventis
Janssen
Bayer
Eli Lilly
HKMA
HKDA
Abbott
2 : 1
1 : 3
1 : 0
4 : 1
Match results for 24 September 2006
Match on 24 September 2006
There were 4 exciting matches between medical societies and
pharmaceutical companies on 24 September 2006. There were
impressive performances by HKOS and Schwarz teams with 5 and 3
goals respectively.
From left to right: Dr Anthony Chan and Dr Michael
Lai (HKOS)
AVC
IDS
AstraZeneca
Wyeth
HKOS
Schwarz
Jacobson
Schering-Plough
0 : 5
0 : 3
0 : 2
0 : 2
Match results for 15 October 2006
Match on 15 October 2006
There were 4 exciting matches between pharmaceutical companies
on 15 October 2006. All teams played well with IDS scoring the
most goals on the day. T. Mountain team from left to right: Chris Cheung,
Frankie Chan, Lai Ka Ho, Wong Tak Po and Sam Liu
Boehringer I/Cardio Soc
T. Mountain
Eli Lilly
Janssen
AVC
IDS
P&G
Schering-Plough
2 : 1
1 : 3
0 : 3
1 : 0
Score
Score
Score
Society News
News fromMember Societies
Australian Doctors and Dentists Association of Hong Kong
New office-bearers for the year are as follows: Chairman: Dr. Dominic WOO, Hon. Secretary: Dr. Francis LEE, Council
Representative: Dr. Dominic WOO.
Hong Kong Institute of Medical Laboratory Sciences Ltd.
New office-bearers for the year are as follows: Chairman: Mr. Yiu-lam TSIM, Hon. Secretary: Ms. Po-chu LAM, Hon.
Treasurer: Mr. Bosco Wan-lung YAU, Council Representative: Mr. Tat-tang CHEUNG.
The NewMedico-Legal Society of Hong Kong
New office-bearers for the year are as follows: President: Mr. Kamlesh Arjan SADHWANI, Hon. Secretary: Mr. Patrick
M. BURKE, Hon. Treasurer: Ms. Kimie BURKE.
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working together with
their societies.
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Match results for 23 September 2006
Match results for 15 October 2006
Date / Time Function Enquiry / Remarks
1 WED
Sugar
Tel: 2572 9255
Fax: 2838 6280
Miss Y.C. YEUNG
Tel: 3119 1858
Fax: 2301 2414
8:30pm - 12:30 pm ୊ஶ݈୛օ౩ষଋጛ፞แ!)UD.IDB.1417*
(3,8,10,15,17,22,24,29)
(13,20,27)
(10,11)
(12)
(12)
Integrative Medicine Forum 2006
Organised by: Hong Kong Association for Integration of Chinese-Western Medicine
Chairman: Prof. Edwin Chau Leung YU # Lecture Theatre, 10/F, TWGHs Yu Chun Keung
Memorial Centre, Kwong Wah Hospital, 25 Waterloo Road, Kowloon
Organised by: College of Nursing, Hong Kong
Sugar
Tel: 2572 9255 Fax: 2838 6280ড়୛օ౩ഗТ݈୛ଋጛ፞แ!)UD.QOD.1317*
Organised by: College of Nursing, Hong Kong
7:30 pm to 9:30 pm
(8,15,22,29)
(12,19,26)
(10,17,24)
(6,7,8,9)
2
THU
Ms. ChristineWONG
Tel: 2527 8285
HKMA Council Meeting
Organised by: The Hong Kong Medical Association # HKMA Headquarter Office, 5/F, Duke
of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm
Ms. Nina HUNG
Tel: 2861 1979
1 CME Point
HKMA Lecture Series with Kennedys Part II: The Standard of Expert Reporting
Orgainsed by: The Hong Kong Medical Association Chairman: Dr. K CHOI Speaker: Mr. J
WALLACE # HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club
Building, 21-22 Connaught Road Central, Hong Kong
2:00 pm
3 FRI
Sugar
Tel: 2572 9255
Fax: 2838 6280
Certificate Course on Quality Management (TC-CQM-0106)
Organised by: College of Nursing, Hong Kong
5 SUN
Ms. Dora HO
Tel: 2527 8285
HKMA Tennis Tournament
Orgainsed by: The Hong Kong Medical Association Chairman: Dr. C.W. CHIN # Kowloon
Tong Club, 113A Waterloo Road, Kowloon Tong, Kowloon
7:30 pm
(9,13,16,20,23,27,30)
6:00 pm - 9:00 pm
Miss Alman LAM
Tel: 2608 3382
Email: almen@union.org.hk
Practical Tips & Pitfalls in Minimally Invasive Surgery
Organised by: Minimally Invasive Centre, Union Hospital & Hong Kong Society of Minimal
Access Surgery Chairman: Anthony P.C. YIM Speaker: Various # Minimally Invasive Centre,
Union Hospital
Ms. Jenny CHAN
Tel: 2871 8871
Fax: 2785 1850
Advances in Paediatric Critical Care
Organised by: Hong Kong College of Paediatricians Chairman: Dr. N.S. TSOI Speaker:
Various # Lecture Theatre, M Floor, HAHO, Kowloon
Mr. Daniel CHOK
Tel: 2871 8896
Fax: 2871 8898
7th Asian Congress on Oral and Maxillofacial Surgery ACOMS
Organised by: Hong Kong Association of Oral and Maxillofacial Surgeons Chairman: Prof.
Nabil SAMMAN Speaker: Various # Hong Kong Convention and Exhibition Centre, Wanchai
6 MON
Ms. Karen CHU
Tel: 2527 8898 Fax: 2865 0345
Certificate Course on Drug Dispensing in Office Clinics
Organised by: The Federation ofMedical Societies of HongKongChairman: Dr. HUNGKwanNgai
Speaker: Dr. LAMTsan&Mr. Peter SUEN # LectureHall, TuenMunHospital, NewTerritories
7 TUE
Miss Nina HUNG
Tel: 2861 1979
1 CME Point
HKMA CME Luncheon Lecture on Comoridity of Anxiety and Depression - New Insight on
Diagnosis and Treatment
Orgainsed by: The Hong KongMedical Association Chairman: Dr. T.C. SHIH Speaker: Prof. J
ZOHAR # Grand Ballroom, Level 2, LanghamHotel, 8 Peking Road, Tsimshatsui, Kowloon
Ms. Tammy TAM
Tel: 2527 8941
HKMA Newsletter Editorial Meeting
Orgainsed by: The Hong KongMedical Association Chairman: Dr. H.H. TSE # HKMA
Headquarter Office, 5/F, Duke ofWindsor Social Service Building, 15 Hennessy Road,Wanchai,
Hong Kong
2:00 pm
8:00 pm
8 WED
9 THU
Dr. Y.C. PO
Tel: 2990 3788 Fax: 2990 3789
2 CME Points
Hong Kong Neurosurgical Society Monthly Academic Meeting - An Update on
Neuroanaesthesia
Organised by: Hong Kong Neurosurgical Society Speaker: Dr A O'REGAN Venue: Seminar
Room, G/F, Block A, Queen Elizabeth Hospital, Kowloon
7:30 am
Miss Nina HUNG
Tel: 2861 1979
(Registration fee is required)
1 CME Point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 2006 (XI)
- Review on Treatment of Primary Liver Cancer
Organised by: The Hong Kong Medical Association & Hong Kong Sanatorium and Hospital
Chairman: Dr. T.C. SHIH Speaker: Dr. W.T. LEUNG # HKMA Dr. Li Shu Pui Professional
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
2:00 pm
11 SAT
Ms. CHANMing Chu
Tel: 2639 1437 / 2639 1438
Fax: 2671 7135
Practical Management of Major Sexually Transmitted Infections in Social Hygiene Service
Organised by: Social Hygiene Service, CHP, DH Speaker: Various # Fanling Social Hygiene
Clinic, 6/F Fanling Integrated Treatment Centre, 2 Pik Fung Road, Fanling, N.T.
Ms. Clara TSANG
Tel: 2354 2440
2 CME Points
HKMA Refresher Course for Health Care Providers 2006/2007 (III) - Urinary Incontinence in
Females
Organised by: The Hong Kong Medical Association & Our Lady of Maryknoll Hospital
Chairman: Dr. T.C. SHIH Speaker: Dr. L.K. YEO # Our Lady of Maryknoll Hospital, 118
Shatin Pass Road, Wong Tai Sin, Kowloon, Hong Kong
2:15 pm - 4:30 pm
2:30 pm
Ms. Terry LEUNG
Tel: 2632 3482Fax: 2647 7432
Email: congress@hkoa.org
15 CME Points
HKOA Annual Congress 2006 - Knee Surgery 2006: In Pursuit of Excellence
Organised by: Hong Kong Orthopaedic Association Chairman: Dr. Wilson LI & Dr. W.M.
TANG Speaker: Various # Cyberport Convention & Exhibition Centre
8:30 am - 5:00 pm
Ms. Gigi MAK
Tel: 2527 8285
HKMA 8th Beijing- Hong Kong Medical Exchange
Organised by: The Hong Kong Medical Association Chairman: Dr. S.W. LI & Dr. T.C. SHIH #
Holiday Inn Golden Mile, 50 Nathan Road, Tsim Sha Tsui, Kowloon, Hong Kong
Ms. Dora HO
Tel: 2527 8285
12 SUN
Ms. Karen CHU
Tel: 2821 3515
Fax: 2865 0345
The Federation's Soccer Five Tournament 2006
Organised by: The Federation of Medical Societies of Hong Kong & The Hong Kong
Association of the Pharmaceutical Industry Chairman: Dr. Godfrey C.F. CHAN # Shek Kip
Mei Park Sports Centre, 290 Nam Cheong Street, Shek Kip Mei, Sham Shui Po
7:00 pm - 11:00 pm
Miss Nina HUNG
Tel: 2861 1979
(Registration fee is required)
3 CME Points
HKMA Structured CME Programme Year 06/07 (VIII) - Psychiatry
Organised by: The Hong Kong Medical Association & Queen Elizabeth Hospital Chairman:
Dr. T.C. SHIH Speaker: Various # Queen Elizabeth Hospital, Lecture Theatre, Block M, G/F,
Queen Elizabeth Hospital
2:00 pm
HKMA Trailwalker 2006
Organised by: The Hong Kong Medical Association Chairman: Dr. C Yu # MacLehose Trail
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28 TUE
Sugar
Tel: 2572 9255 Fax: 2838 6280
1.5 CME Points
Management Interest Group - Seminar onੑੑࡥ੉໠໠ЖЖώհฒྮ኏"" (SMIG-04-06)
Organised by: College of Nursing, Hong Kong Speaker: Dr. Alex CHEUNG
6:30 pm - 8:00pm
Date / Time Function Enquiry / Remarks
12 SUN
Hospital Administration Department
Tel: 2835 8800 Fax: 2835 8008
E-mail:hospadm@hksh.com,
Website: http://www.hksh.com/CME.pdf
(15,20,22,27,29)
(16,17)
(23,30)
2nd Certificate Course in Recent Medical Advances for General Practitioners
Jointly organized by the Family Medicine Unit, the University of Hong Kong and the Family
Medicine Division, Hong Kong Sanatorium and Hospital Speakers: Various
Organised by: College of Nursing, Hong Kong13 MON
15 WED
Sugar
Tel: 2572 9255
Fax: 2838 6280
6:30 pm - 9:30 pm
16 THU
Miss Nina Hung
Tel: 2861 1979
1 CME Point
Sugar
Tel: 2572 9255 Fax: 2838 6280
2 CME Points
HKMA CME Luncheon Lecture on Medico-legal Seminar
Organised by: The Hong Kong Medical Association Chairman: Dr. K CHOI Speaker: Dr. M.K.
TEOH # Crystal Ballroom, Basement 3, Holiday Inn Golden Mile HK, 50 Nathan Road,
Tsimshatsui, Kowloon, Hong Kong
Clinical Nurse Specialist Group Evening Forum - Topic: Overview of Urinary Incontinence
(SCNSG-06-03)
Organised by: College of Nursing, Hong Kong Speaker: Mr. LUI Ka Lok
2:00 pm
6:00 pm - 8:30 pm
Congress Secretariat
Tel: 2855 4235 / 2818 0232
Fax: 2818 1186
Email: hkjcc06@hku.hk
Website: www.hkicc.org
13th Hong Kong International Cancer Congress & 3rd Annual Meeting of Centre for Cancer
Research
Organised by: The Faculty of Medicine of The University of Hong Kong & The Cancer Centre
of Queen Mary Hospital # Cheung Kung Hai Conference Centre, William MWMong Block Li
Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam
Road, Hong Kong
Dr. W.M. CHAN / Dr. C.M. CHU
Tel: 2855 5841 / 2855 5824
Fax: 2855 9667
(1) An Atypical Disease Presenting Atypically
(2) An Elderly Gentleman With Lung Infiltrates and Renal Impairment
Organised by: Hong Kong Thoracic Society / ACCP (HK &Macau Chapter) Chairman: Dr.
W.C. YU & Dr. M.L.WONG Speaker: Dr. Y.C. YEUNG & Dr. C.W. CHOW # LG1, Lecture
Room, Ruttonjee Hospital, Wanchai
6:30 pm - 8:00 pm
18 SAT
Sugar
Tel: 2572 9255 Fax: 2838 6280
2 CME Points
Research Symposium - Topic: Research Partnership Among Service, Education and Research Sectors
Organised by: College of Nursing, Hong Kong Speaker: Various
9:30 am - 12:30 pm
24 FRI
Miss Nina HUNG
Tel: 2861 1979
1 CME Point
HKMA CME Luncheon Lecture on The Long-term Cardiovascular Safety for a COX-2
Specific Inhibitor, Etoricoxib - The MEDAL Program
Organised by: The Hong Kong Medical Association Chairman: Dr. T.C. SHIH Speaker: Prof. S
NAVARRA # Grand Ballroom, Level 2, Langham Hotel Hong Kong, 8 Peking Road,
Tsimshatsui, Kowloon, Hong Kong
2:00 pm
Sugar
Tel: 2572 9255
Fax: 2838 6280
Advanced Wound Care Management (TC-AWCM-0106-CNSG)
Organised by: College of Nursing, Hong Kong Speaker: Various
6:00 pm - 8:00 pm
19 SUN
Ms. Dora HO
Tel: 2527 8285
HKMA Family Sports Day
Organised by: The Hong Kong Medical Association Chairman: Dr. C.F. YEUNG # Stanley Ho
Sports Centre, 10 Sha Wan Drive, Pokfulam, Hong Kong
1:30 pm
26 SUN
Miss Nina HUNG
Tel: 2861 1979
(Registration fee is required)
3 CME Points
HKMA Structured CME Programme Year 06/07 (VIII) - Endocrinology
Organised by: The Hong Kong Medical Association and Kwong Wah Hospital Chairman: Dr.
T.C. SHIH Speaker: Various # Kwong Wah Hospital, Lecture Theatre, 10/F., Yu Chun Keung
Medical Memorial Centre, Kwong Wah Hospital, Kowloon
2:00 pm
ᚂᕛ៖౩லҢ़ᇭߑ໦ (SUSMH 025 0 B)
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Meetings
9th International Symposium on Thrombolysis and Acute Stroke Therapy (TAST 2006) & 19th Annual Scientific Meeting of The Hong
Kong Neurological Society
Organised by: The Hong Kong Neurological Society, Chinese Society of Neurology & The Hong Kong Polytechnic University
(Rehabilitation Science Department) Speaker: Various # Jockey Club Auditorium, The Hong Kong Polytechnic University Enquiry:
Conference Secretariat Email: tast2006@icc.com.hk Website: www.tast2006.com
Hong Kong Ophthalmological Symposium 2006 - Theme: Glaucoma
Organised by: College of Ophthalmologists of Hong Kong, Euro Asia Congress Chairman: Prof. Clement C.Y. THAM Speaker: Prof.
Robert STEGMANN # Hong Kong Convention & Exhibition Centre, Wanchai Enquiry: Ms. Vicki WONG Tel: 2761 9128 Fax:2715 0089
G B Ong Lecture: Live Surgery - A New Specialty
Organised by: The American College of Surgeons, Hong Kong Chapter & Department of Surgery, Li Ka Shing Faculty of Medicine, The
University of Hong Kong Speaker: Prof. Henri BISMUTH # Underground Lecture Theatre, New Clinical Building, Queen Mary Hospital,
Pokfulam Road, Hong Kong Enquiry: Forum Secretary Tel: 2855 4885/2855 4886 Fax: 2819 3416 Email: hksf@hkucc.hku.hk Website:
http://www.hku.hk/surgery
International Colorectal Disease Symposium (ICDS) 2007
Organised by: Hong Kong Society for Coloproctology & Pamela Youde Nethersole Eastern Hospital (Department of Surgery) Chairman:
Mr. Michael K.W. LI Speaker: Various # 2/F NewWing, Hong Kong Convention & Exhibition Centre, Wanchai Enquiry: Ms. Olivia HO
Tel: 2595 6362 Fax: 2515 3195
Cardio Rhythm 2007
Organised by: Hong Kong College of Cardiology & Chinese Society of Pacing and Electrophysiology # Hong Kong Convention &
Exhibition Centre, Wanchai Enquiry: Secretariat, CMP Medica Pacific Limited Tel: 2559 5888 Fax: 2559 6910 Email:
info@cardiorhythm.comWebsite: www.cardiorhythm.com
1-3/12/2006
9-10/12/2006
13/1/2006
25-27/01/2007
2-4/02/2007
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Match results for 23 September 2006
Meetings
s
Calendar of Events
Courses
健康服務助理員訓練課程 (TC-HCA-0306)
Organised by: College of Nursing, Hong Kong Enquiry: Sugar Tel: 2572 9255 Fax: 2838 6280
Certificate Course on Quality Management (TC-CQM-0106)
Organised by: College of Nursing, Hong Kong Enquiry: Sugar Tel: 2572 9255 Fax: 2838 6280
醫療護理常用英語初階 (SUSMH 025 0 B)
Organised by: College of Nursing, Hong Kong Sugar Tel: 2572 9255 Fax: 2838 6280
家務助理陪月服務訓練課程 (TC-PNC-0206)
Organised by: College of Nursing, Hong Kong Enquiry: Sugar Tel: 2572 9255 Fax: 2838 6280
Advanced Wound Care Management (TC-AWCM-0106-CNSG)
Organised by: College of Nursing, Hong Kong Speaker: Various Enquiry: Sugar Tel: 2572 9255 Fax: 2838 6280
Pre-hospital Trauma Life Support (PHTLS) Provider Course
Organised by: Department of Surgery, University of Hong Kong and Hong Kong Chapter of the American College of Surgeons
Enquiry: Course Secretariat, Department of Surgery, University of Hong Kong Medical Centre Tel: 2530 8016
2nd Certificate Course in Recent Medical Advances for General Practitioners
Jointly organized by the Family Medicine Unit, the University of Hong Kong and the Family Medicine Division, Hong Kong
Sanatorium and Hospital Speakers: Various, Enquiry: Hospital Administration Department Tel: 2835 8800, Fax: 2835 8008,
E-mail:hospadm@hksh.com, Website: http://www.hksh.com/CME.pdf
醫療護理常用英語初階 (SUSMH 026 0 B)
Organised by: College of Nursing, Hong Kong Sugar Tel: 2572 9255 Fax: 2838 6280
1,6,8,13,15,20,22,27,29/12/2006
3,5,10,12,17,19,24,26,31/01/2007
2,7,9,14,16,28/02/2007
2,7,9,14,16,21,23,28,30/03/2007
1,8,15,29/12/2006
4,6,11,13/12/2006
4,7,11,14/12/2006
7/12/2007
10&17/12/2006
17/12/2006
21/1/2007, 11/2/2007
18/3/2007, 22/4/2007
20/5/2007, 17/6/2007
18,20,27/12/2006
3,8,10,15,17,22,24/1/2007
Upcoming Certificate Courses of the Federation of Medical Societies of Hong Kong
6 Nov 06 - 11 Dec 06 (Mon)
6 Nov 06 - 27 Nov 06
8 Nov 06 - 13 Dec 06 (Wed)
17 Nov 06 - 29 Dec 06 (Fri)
(except 22 Dec 06)
3 Jan 07 - 7 Feb 07 (Wed)
9 & 16 Jan 07 (Tue)
Hong Kong Society of Sleep
Medicine
Hong Kong Society for the
Study of Thalassaemia
Hong Kong Society for
Emergency Medicine & Surgery
Public
Medical & health
professionals
Medical & health
professionals
Health care
professionals
Medical & health
professionals
Medical & health
professionals
Certificate Course on Sleep
Health & Disorders
Certificate Course on Drugs
Dispensing in Office Clinic
Certificate Course on Diagnosis,
Prevention and Management of
Thalassaemia
Certificate Course on Wilderness
Medicine for Healthcare
Professionals
Certificate course on Medical
Genetics
Certificate Course on Drugs
Safety in Old Aged Home
C106
C113
C98
C103
C111
C112
Date Course No Co-organiserCourse Name Target Participants
Cancer Imaging 2007 - Joint M eting of th International Cancer Imaging Society & Hong Kong College of Radiologists
Organised by: International Cancer Imaging Society & Hong Kong College of Radiologists Chairman: Ms. Lilian LEONG Speaker:
Various # Hong Kong Academy of Medicine Jockey Club Building Enquiry: Mrs. Maureen WATTS Tel: 44 (0) 208 661 3420 Fax: 44 (0) 208
661 3901 E-mail: Maureen.Watts@icr.ac.uk or Ms. Diane LEE Tel: 2871 8788 Fax: 2554 0739 E-mail: enquiries@hkcr.org
The 21st Congress of International Association of Paediatric Dentistry IAPD
Organised by: Hong Kong Society of Paediatric Dentistry # Hong Kong Convention & Exhibition Centre, Wanchai Enquiry: Mr. Daniel
CHOK Tel: 2871 8896 Fax: 2871 8898 Email: info@iapd2007.comWebsite: http://www.iapd2007.com
10-11/02/2007
13-17/06/2007
28
CME/CPEAccreditation applied for
For downloading the application form, please refer to our website:
http://www.fmshk.org
3 January 2007 to 7 February 2007 (Every Wednesday)
7:00 p.m. - 8:30 p.m.
Lecture Hall, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong
HK$960 (6 Sessions)
English
Awarded to participants with a minimum attendance of 70%
The Secretariat of the Federation of Medical Societies of Hong Kong
The field of medical genetics has seen rapid advances in the last ten to twenty years, especially so
with the knowledge brought about by the Human Genome Project. This course aims to provide the
participants an overview and update in this field, so that they can appreciate how the practice of
medicine is changing with the genetic advances.
Date
Time
Venue
Course Fee
Language
Certificate
Enquiry
:
:
:
:
:
:
:
Tel. : 2527 8898 Fax: 2865 0345 Email: info@fmshk.org
Date Topic Lecturer
Cer tificate Course on Medical Genetics
CERTIFICATE COURSE FOR MEDICALAND HEALTH PROFESSIONALS
Jointly organised by
(Course no. C111)
The Federation of Medical Societies of Hong Kong
ॷ෫ᚂᏰಢᙑᖒོ
ᚂᏰᒸ༈Ᏸᜌਪ፞แ
ॷ!!෫!!ᚂ!!Ᏸ!!ᒸ!!༈!!Ᏸ!!ོ
Hong Kong Society of Medical Genetics
Medical Genetics in Hong Kong - An Overview
ᚂᏰᒸ༈Ᏸӵॷ෫ޟ྅។
Genetic Counseling
ᒸ༈ሄᏲ
Chromosomal Disorders in Hong Kong
ॷ෫ޟࢗՓᡝ੽੾
Application of Molecular Genetics in Patient Care
Ϸυᒸ༈ᏰޟᖝחᔖҢ
Prenatal Diagnosis & Therapy
౰ࠉຨᘞЅݽᕛ
Treatment Strategies in Genetic Diseases
ᒸ༈੾ޟᕛݲ
Dr. Stephen Lam
ݓኈ౏ᚂҡ
Dr. Ivan Lo
ᑋᎃМᚂҡ
Mr. Chan Wing-kwong
ങҗӎଽ઻Ͻᡛৱ
Dr. Brian Chung
ᗩٿِᚂҡ
Dr. Leung Kwok-yin
గ୽፱ᚂҡ
Dr. Larry Baum
ѓҳܑിρ
Dr. Richard Choy
ጾӎ୉ിρ
3 January 2007
10 January 2007
17 January 2007
24 January 2007
31 January 2007
7 February 2007
Objective:
28
CME/CPEAccreditation applied for
For downloading the application form, please refer to our website:
http://www.fmshk.org
9 & 16 January 2007
7:00 p.m. - 8:30 p.m.
Lecture Hall, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong
HK$350 (2 Sessions)
Cantonese (Supplemented with English)
Awarded to participants with a minimum attendance of 70%
The Secretariat of the Federation of Medical Societies of Hong Kong
Date
Time
Venue
Course Fee
Language
Certificate
Enquiry
:
:
:
:
:
:
:
Tel. : 2527 8898 Fax: 2865 0345 Email: info@fmshk.org
Cer tificate Course on Drugs Safety in
Old Aged Home
Objective: To enhance safety of drugs handling in old aged home
Common Drugs Used in Elder ly Homes
9 January 2007
16 January 2007
(Course No. C112 )
THE FEDERATION OF MEDICAL SOCIETIES OF HONG KONG
ॷ ෫ ᚂ Ᏸ ಢ ᙑ ᖒ ོ
ԊՂ଱޾லَ᛾ސ
Mr. Henry Chanങසറ
ॷ෫ຝы᛾ᏘৱЅॷ෫᛾Ᏸོཆٱ
Management of Drugs
೎౩⠹ސޟনࠌ!
2/!ׂ๡ᓽԆ⠹ސ
3/!ғጂࣂี⠹ސ
4/!ߴٺၭᚂᡥ݈⠹
Ms. Rebecca Po-wah Poon
28
Cer tificate Course on Drug Dispensing in Office Clinics
Objective: To enhance safety and efficacy of clinic assistants in drug
dispensing in office clinics
(Course No. C113 )
THE FEDERATION OF MEDICAL SOCIETIES OF HONG KONG
ॷ ෫ ᚂ Ᏸ ಢ ᙑ ᖒ ོ
ຨܚ᛾ސ೎౩Ѕ଩᛾அҏ፞แ
Drug Classification in Hong Kong - A Simple
Approach Common Drugs Identifications in Clinic
Mr. Peter Suen ୪ᤌᛞ٣س
֚ԫ᠔೭ࢬ᜔ᢐᕪஃ Clinic Dispensing Management
Mr. Peter Suen ୪ᤌᛞ٣س
֚ԫ᠔೭ࢬ᜔ᢐᕪஃ
Good Dispensing Guidelines
Dr. Lam Tsan
୮அ᠔ᖂ᥽ം᠔س Drugs Stock Keeping and Recording
Mr. Peter Suen ୪ᤌᛞ٣س
֚ԫ᠔೭ࢬ᜔ᢐᕪஃ
ॷ෫᛾ސϷ᜸ᙏϭЅຨܚ᛾ސᜋտ
! 3117ԑ22Т24Р
يԁ଩᛾Ԉࠌ!
ຨܚ଩᛾ᆓ౩
ຨܚ᛾ࠢ৲ԆЅ଄ᓃ
3117ԑ22Т7Р
! 3117ԑ22Т31Р
3117ԑ22Т38Р
Р ෈ ; 3117ԑ22Т7РՍ3117ԑ22Т38Р
ਢ ໢ ; ήϿ3ਢՍ4ਢ41Ϸ
Ӵ ᘈ ; Аߞᚂ଱ᅋᖿᢈȂཱིࣨАߞߧݘᢎၾ
ԝ າ ; ؐ՝෫ᄌ%611ϯ)5ஆ*
ᇭ ِ ; ဃᇭ
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THE FEDERATION OF MEDICAL SOCIETIES OF HONG KONG
ॷ ෫ ᚂ Ᏸ ಢ ᙑ ᖒ ོ

